Nucleic acid agent for inducing g-quadruplex structure

The nucleic acid agent with a single-base insertion type g-AS sequence improves the stability and specificity of guanine quadruplex structures with target RNAs, addressing the limitations of self-guanine quadruplex formation and enhancing therapeutic efficacy by forming stable targeted structures.

WO2024228398A1PCT designated stage expired Publication Date: 2024-11-07NAT UNIV CORP TOKYO MEDICAL & DENTAL UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/016878
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-02
Filing Date
2024-05-02
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current nucleic acid medicines using antisense methods face limitations in effectiveness due to the formation of self-guanine quadruplex structures, which can reduce the stability and specificity of guanine quadruplex structures with target RNAs, impacting their therapeutic efficacy.

Method used

Development of a nucleic acid agent with a single-base insertion type G-tethered antisense oligonucleotide (g-AS) that suppresses the formation of self-guanine quadruplex structures while maintaining the ability to form targeted guanine quadruplex structures, using sequences like GXGG or GGXG, where X is a base other than G or C, to enhance stability and specificity.

Benefits of technology

The nucleic acid agent forms a more stable guanine quadruplex structure with the target RNA, reducing off-target effects and enhancing the therapeutic efficacy by selectively inducing loop structures and inhibiting protein translation or reverse transcription.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024016878_07112024_PF_FP_ABST
    Figure JP2024016878_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The problem addressed is to provide a new technique for improving the effectiveness of a nucleic acid medicine. The present invention provides a nucleic acid agent capable of binding to a target nucleic acid molecule that includes a guanine-repeated sequence comprising a base sequence GGG, wherein the nucleic acid agent includes a base sequence complementary to at least a portion of the target nucleic acid molecule, two continuous guanine sequences each comprising a base sequence GGG, and a guanine-rich sequence comprising a base sequence GXGG or GGXG, the X representing a base other than G or C or an abasic site, and the two continuous guanine sequences, the guanine-rich sequence, and the guanine-repeated sequence can form a G-quadruplex structure more stable than G-quadruplex structures that can be formed mutually by a plurality of the nucleic acid agents.
Need to check novelty before this filing date? Find Prior Art

Description

Nucleic acid agents for inducing G-quadruplex structures

[0001] The present invention relates to a nucleic acid agent, a double-stranded nucleic acid complex, a pharmaceutical composition, etc., capable of binding to a target nucleic acid molecule.

[0002] In recent years, oligonucleotides have attracted attention in the ongoing development of pharmaceuticals known as nucleic acid drugs, and in particular, the development of nucleic acid drugs using antisense methods is being actively pursued due to their high selectivity for target genes and low toxicity. The antisense method involves selectively modifying or inhibiting the expression of proteins encoded by target genes or the activity of miRNAs by introducing complementary oligonucleotides (antisense oligonucleotides; often referred to herein as "ASOs (Antisense Oligonucleotides)") into cells, using a partial sequence of mRNA or miRNA transcribed from a target gene as the target sense strand.

[0003] As a nucleic acid utilizing the antisense method, the present inventors have developed a double-stranded nucleic acid complex (heteroduplex oligonucleotide (HDO)) in which an antisense oligonucleotide is annealed to its complementary strand (Patent Documents 1 and 2, Non-Patent Documents 1 and 2). The double-stranded nucleic acid complex is a groundbreaking technology with a high antisense effect.

[0004] New technologies are needed to further improve the effectiveness of nucleic acid drugs that utilize antisense methods.

[0005] International Publication No. 2013 / 089283 International Publication No. 2014 / 192310

[0006] Nishina K, et al., "DNA / RNA heteroduplex oligonucleotide for highly gene silencing", Nature Communications, 2015, 6:7969.Asami Y, et al., "Drug delivery system of efficient therapeutic oligonucleotides", Drug Discoveries & Therapeutics. 2016; 10(5):256-262.Hagihara M, et al., "Antisense-induced guanine quadruplexes "inhibit reverse transcription by HIV-1 reverse transcriptase", J. Am. Chem. Soc., 2010, 132:11171-11178.

[0007] The objective of the present invention is to provide a new technology for improving the effectiveness of nucleic acid medicines.

[0008] G-quadruplexes, or Gq structures, are known to form stable nucleic acid structures, such as G-quadruplexes (Gq), which are formed by repeating four G-quadruplexes. For example, mRNAs containing four G-quadruplexes can form intramolecular G-quadruplexes, inhibiting protein translation.

[0009] "G-tethered ASOs" (g-AS) are improved nucleic acid drugs that contain a region containing consecutive guanines that can form a G-quadruplex structure with the guanine repeat sequence in the target RNA, and an antisense region that is complementary to a portion of the target RNA (Hagihara M, et al., J. Am. Chem. Soc., 2010, 132:11171-11178). g-AS can artificially induce G-quadruplex structures with various target RNAs, and can induce a loop structure between the G-quadruplex-induced sequence in the target nucleic acid molecule and the target sequence to which the antisense region hybridizes (Figure 1). g-AS can block the function of various RNA modifiers, such as miRNAs, RNA-binding proteins, translation factors, and splicing factors, through steric hindrance based on the loop structure (Figure 2).

[0010] To address this issue, the present inventors developed a g-AS containing three consecutive guanine repeats (GGG) that can form G-quadruplexes with a guanine repeat sequence in a target nucleic acid molecule. They then analyzed the G-quadruplexes induced by the g-AS. The results revealed that g-AS can form G-quadruplexes between itself and the guanine repeat sequence in the target RNA (hereinafter referred to as "targeted G-quadruplexes"), as well as G-quadruplexes between itself and the target RNA independently (hereinafter referred to as "self-G-quadruplexes"). These findings suggest that the formation of self-G-quadruplexes may suppress the formation of targeted G-quadruplexes, thereby reducing the efficacy of g-AS.

[0011] Therefore, the present inventors created a new g-AS capable of suppressing the formation of self-G-quadruplexes: a single-base-insertion g-AS in which a single base other than G was inserted into the consecutive guanine sequence GGG. The present inventors found that the single-base-insertion g-AS suppressed the formation of self-G-quadruplexes while maintaining the ability to form targeted G-quadruplexes, thereby enhancing the effect of g-AS.

[0012] The present invention is based on the above findings and provides the following: (1) A nucleic acid agent capable of binding to a target nucleic acid molecule containing a guanine repeat sequence consisting of the nucleotide sequence GGG, the nucleic acid agent comprising: a target-binding sequence containing a nucleotide sequence complementary to at least a portion of the target nucleic acid molecule; two consecutive guanine sequences, each consisting of the nucleotide sequence GGG; and a guanine-rich sequence consisting of the nucleotide sequence GXGG or GGXG, where X represents a base other than G or C or an abasic site; the two consecutive guanine sequences, the guanine-rich sequence, and the guanine repeat sequence can form a guanine-quadruplex structure that is more stable than a guanine-quadruplex structure that can be formed by a plurality of the nucleic acid agents together. (2) The nucleic acid agent according to (1), wherein the two consecutive guanine sequences and the guanine-rich sequence are located at the 5'-end or 3'-end of the target-binding sequence. (3) The nucleic acid agent according to (2), wherein the guanine-rich sequence is located at the 5'-end or 3'-end of, or between, the two consecutive guanine sequences. (4-1) The nucleic acid agent according to (2) or (3), wherein the guanine-rich sequence is located between the two consecutive guanine sequences.(4-2) (a) in the nucleic acid agent, the two consecutive guanine sequences and the guanine-rich sequence are located on the 5'-end side of the target binding sequence, and (ai) the guanine-rich sequence is located on the 5'-end side of the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG, or (a-ii) the guanine-rich sequence is located between the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG, or (a-iii) the guanine-rich sequence is located on the 3'-end side of the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GGXG, or (b) in the nucleic acid agent, the two consecutive guanine sequences and the guanine-rich sequence are located on the 3'-end side of the target binding sequence, and (bi) the guanine-rich sequence is located on the 5'-end side of the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GGXG, (b-ii) The guanine-rich sequence is located between the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG, or (b-iii) The guanine-rich sequence is located on the 3'-end side of the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG, where X in the base sequence represents a base other than G or C, or an abasic site. (5) The nucleic acid agent according to any of (3) to (4-2), which includes a linker sequence consisting of one or more bases other than G or C between two adjacent sequences of the two consecutive guanine sequences and the guanine-rich sequence. (6) The nucleic acid agent according to (5), which includes a linker sequence having a length of 1 to 30 bases. (7) The nucleic acid agent according to any of (2) to (6), which includes a spacer sequence or spacer molecule between the two consecutive guanine sequences and the guanine-rich sequence and the target binding sequence. (8) The nucleic acid agent according to (7), wherein the spacer sequence is 1 to 10 bases in length. (9) The nucleic acid agent according to any one of (2) to (6), wherein no spacer sequence is present between the two consecutive guanine sequences and the guanine-rich sequence and the target binding sequence.(10) The nucleic acid agent according to any one of (1) to (9), which does not contain the base sequence GGG and / or does not contain the base sequence CCC other than the two consecutive guanine sequences. (11) The nucleic acid agent according to any one of (1) to (10), wherein X is T, A, or U. (12) The nucleic acid agent according to any one of (1) to (11), wherein in the guanine-rich sequence, the nucleoside containing a guanine base and the nucleoside containing the base represented by X are a ribonucleoside and a deoxyribonucleoside, respectively, or a deoxyribonucleoside and a ribonucleoside, respectively. (13) The nucleic acid agent according to any one of (1) to (12), wherein the target binding sequence is 12 to 30 bases in length. (14) The nucleic acid agent according to any one of (1) to (13), which contains natural nucleosides and / or unnatural nucleosides. (15) The nucleic acid agent according to (14), wherein the unnatural nucleoside is selected from the group consisting of a 2'-modified nucleoside, a 5'-modified nucleoside, and a bridged nucleoside. (16) The nucleic acid agent according to any one of (1) to (15), comprising or consisting of a morpholino nucleic acid. (17) The nucleic acid agent according to any one of (1) to (16), wherein all or part of the internucleoside linkages of the nucleic acid agent are modified internucleoside linkages. (18) The nucleic acid agent according to (17), wherein the modified internucleoside linkages are phosphorothioate linkages. (19) The nucleic acid agent according to any one of (1) to (18), comprising a modified nucleobase. (20) The nucleic acid agent according to any one of (1) to (19), wherein the target nucleic acid molecule comprises a loop-forming sequence between the target sequence to which the target binding sequence binds and the guanine repeat sequence. (21) The nucleic acid agent according to (20), wherein the loop-forming sequence is 1 to 500 bases in length. (22) The nucleic acid agent according to any one of (1) to (21), for inducing steric blocking of the target nucleic acid molecule. (23) The nucleic acid agent according to any one of (1) to (22), wherein the target nucleic acid molecule is a target gene or a transcription product thereof. (24) The nucleic acid agent according to (23), for inducing exon skipping or exon inclusion of the transcription product. (25) The nucleic acid agent according to any one of (1) to (24), wherein the target nucleic acid molecule is RNA or DNA.(26) The nucleic acid agent according to (25), wherein the RNA is mRNA or a precursor thereof, non-coding RNA, or viral RNA. (27) The nucleic acid agent according to (26), for suppressing translation of the mRNA. (28) The nucleic acid agent according to (26), for suppressing or inhibiting reverse transcription of the viral RNA. (29) A double-stranded nucleic acid complex comprising a first nucleic acid strand consisting of the nucleic acid agent according to any one of (1) to (28), and a second nucleic acid strand comprising a base sequence complementary to the first nucleic acid strand. (30) The double-stranded nucleic acid complex according to (29), wherein the second nucleic acid strand comprises a ribonucleoside, a deoxyribonucleoside, and / or a modified nucleoside. (31) The double-stranded nucleic acid complex according to (29), wherein the second nucleic acid strand comprises: bases non-complementary to the first nucleic acid strand, an inserted sequence and / or a deletion, and / or at least one overhang region located on the 5'-terminal side and / or the 3'-terminal side of a region consisting of a base sequence complementary to the first nucleic acid strand. (32) The double-stranded nucleic acid complex according to (31), wherein the overhang region is 1 to 30 bases long. (33) The double-stranded nucleic acid complex according to any one of (29) to (32), wherein the second nucleic acid strand is bound to a functional moiety. (34) The double-stranded nucleic acid complex according to (33), wherein the functional moiety is a lipid. (35) The double-stranded nucleic acid complex according to (34), wherein the lipid is selected from the group consisting of cholesterol or an analog thereof, tocopherol or an analog thereof, folic acid, phosphatidylethanolamine, and a substituted or unsubstituted hydrocarbon group having 16 to 30 carbon atoms. (36) The double-stranded nucleic acid complex according to any one of (29) to (35), wherein the first nucleic acid strand and the second nucleic acid strand are linked via a linker. (37) The double-stranded nucleic acid complex according to (36), wherein the linker is a cleavable or non-cleavable linker. (38) A pharmaceutical composition comprising the nucleic acid agent according to any one of (1) to (28) or the double-stranded nucleic acid complex according to any one of (29) to (37). (39) The pharmaceutical composition according to (38), for treating or preventing a neuromuscular disease, an infectious disease, an inflammatory disease, cancer, an immune disease, an ischemic disease, or a metabolic disease.(40) The pharmaceutical composition according to (39), wherein the neuromuscular disease is a neurological disease, a muscular disease, a neuromuscular junction disease, a neurodegenerative disease, or a muscular dystrophy. (41) The pharmaceutical composition according to (39), wherein the infectious disease is a viral infection. (42) The pharmaceutical composition according to any of (38) to (41), which is administered intravenously, subcutaneously, intramuscularly, intrathecally, orally, intraperitoneally, nasally, or by inhalation. (43) The pharmaceutical composition according to any of (38) to (42), wherein the nucleic acid agent or the double-stranded nucleic acid complex is administered in an amount of 0.1 mg to 200 mg. (44) A toxicity-reducing agent for a G-quadruplex structure, comprising a guanine-rich sequence consisting of the base sequence GXGG or GGXG, wherein X represents a base other than G or C or an abasic site, and which can reduce the toxicity of a G-quadruplex structure compared to a G-quadruplex structure composed of four consecutive guanine sequences, each consisting of the base sequence GGG. (45) The toxicity reducer according to (44), which contains one, two, or three consecutive guanine sequences, each consisting of the base sequence GGG. (46) The toxicity reducer according to (45), which is for forming a G-quadruplex structure with a target nucleic acid molecule containing a guanine repeat sequence consisting of the base sequence GGG. This specification includes the disclosure of Japanese Patent Application No. 2023-076064, from which the present application claims priority.

[0013] According to the present invention, a novel G-tethered ASO (g-AS) is provided that suppresses the formation of a self-G-quadruplex structure.

[0014] Figure 1 shows a schematic representation of the G-quadruplex (Gq) structure formed by a G-tethered ASO (g-AS) and a guanine repeat sequence consisting of the base sequence GGG in a target RNA. The target RNA forms a loop structure between the guanine repeat sequence and the target sequence, inducing steric hindrance and other effects. Figure 2 shows the effects that g-AS can have on target RNA. Figure 2A shows the effect on splicing factors and other factors due to the induction of a loop structure. Figure 2B shows the functional inhibition of reverse transcriptase due to the induction of a loop structure. Figure 3 shows the sequences of intron 23, exon 23, and intron 23 in the dystrophin gene of mdx mice (a model mouse for Duchenne muscular dystrophy). In the figure, lowercase letters indicate introns, and uppercase letters indicate exons. The "target sequence (a)" indicated by a solid black frame and the "target sequence (b)" indicated by a dashed black frame indicate the position of the target sequence to which the target binding sequence of g-AS hybridizes in the examples. The "GGG sequence" indicates the guanine repeat sequence targeted by g-AS. Figure 4 shows the structure of g-AS. As sequences for forming a G-quadruplex with the guanine repeat sequence in the target RNA, 5'g-AS(a)-original contains three consecutive guanine sequences (nucleotide sequence GGG) on the 5' side of the target binding sequence, while single-base-inserted g-AS contains two consecutive guanine sequences (nucleotide sequence GGG) and one guanine-rich sequence (nucleotide sequence GTGG or GGTG). Figure 5 shows the results of evaluating the formation of a G-quadruplex structure by 5'g-AS(a)-original. Figure 5A shows the thioflavin T (ThT) assay results for G-quadruplex formation of 5'g-AS(a)-original in the presence of target mdx RNA ("RNA + g-AS" in the figure) and in the absence of target mdx RNA ("g-AS" in the figure). Figure 5B shows the G-quadruplex structure formed by g-AS molecules independently of the target nucleic acid molecule (self-G-quadruplex structure). Figure 6 shows the ThT assay results for G-quadruplex formation of 5'g-AS(a)-original and single-base-inserted g-AS in the absence of target mdx RNA.Figure 6A shows the position of the single-base (T base) insertion in the single-base-inserted g-AS. Figure 6B shows the results of a ThT assay. Figure 7 shows the results of quantification of G-quadruplex formation by g-AS in the presence of target mdx RNA ("RNA + g-AS" in the figure) and in the absence of target mdx RNA ("g-AS" in the figure) for 5'g-AS(a)-original and single-base-inserted g-AS. Figure 7A shows the results for 5'g-AS(a)-original. Figure 7B shows the results for 5'g-AS(a)2-1, a single-base-inserted g-AS. Figure 8 shows the relative fluorescence intensity peak in the presence of target mdx RNA, relative to the fluorescence intensity peak in the absence of target mdx RNA. Figure 8A shows the results for 5'g-AS(a)-original. Figure 8B shows the results for 5'g-AS(a)2-1, a single-base-insertion g-AS. Figure 9 shows a schematic representation of the G-quadruplex (Gq) formed by the single-base-insertion g-AS. Figure 9A shows the stability of the G-quadruplex (targeted Gq) formed by the single-base-insertion g-AS with the target RNA. Figure 9B shows the instability of the G-quadruplex (self-Gq) formed by the single-base-insertion g-AS in the absence of target RNA. Figure 10-1 shows the results of exon skipping induced in cultured cells by the single-base-insertion g-AS and a conventional g-AS without the single-base insertion. Figure 10-1A shows the induction of a 141-bp nucleic acid fragment by skipping exon 23. Figure 10-1B shows the results of induced exon skipping. Figure 10-1C shows the quantitative results of exon skipping efficiency for 5'g-AS(2'OMe)2-1, a single-base insertion g-AS, and 5'g-AS(2'OMe) original, a conventional g-AS without the single-base insertion. Figure 10-2 shows the results of exon skipping induced in vivo in mdx mice by the single-base insertion g-AS and the conventional g-AS without the single-base insertion. Figure 10-2A shows the experimental schedule. Figure 10-2B shows the electrophoresis results. Figure 10-2C shows the quantitative results of exon skipping efficiency when each g-AS was administered.Figure 11-1 shows the inhibition of reverse transcription by a single-base-inserted g-AS. Figure 11-1A shows a schematic representation of the generation of shorter-than-full-length cDNAs when the G-quadruplex formed by g-AS on target mRNAs terminates reverse transcription. Figure 11-1B shows a schematic representation of steric hindrance to reverse transcriptase. Figure 11-1C shows the results of fragment analysis demonstrating the detection of shorter-than-full-length cDNAs. The "Control" in the figure represents the results of reverse transcription reactions performed in the absence of g-AS. Figure 11-2 shows a schematic representation of the reduced off-target effects of a single-base-inserted g-AS. Figure 11-2A shows that a conventional g-AS without a single-base insertion can form a G-quadruplex even for the GAGG sequence, which is similar to the GGG sequence. Figure 11-2B shows that the single-base-inserted g-AS has improved specificity for the GGG sequence, resulting in reduced off-target effects. Figure 12 shows the structures of 3'g-AS(a)-original, which contains a consecutive guanine sequence at the 3' end, and various single-base-inserted g-ASs containing consecutive guanine sequences and guanine-rich sequences at the 3' end. Figure 13 shows the results of quantifying G-quadruplex formation in the absence of target mdx RNA for 3'g-AS(a)-original and single-base-inserted g-ASs using a ThT assay. Figure 14 shows the structures of 5'g-AS(b)-original, which contains consecutive guanine sequences at the 5' end, and various single-base-inserted g-ASs containing consecutive guanine sequences and guanine-rich sequences at the 5' end. Figure 15 shows the results of quantifying G-quadruplex formation in the absence of target mdx RNA for 5'g-AS(b)-original and single-base-inserted g-ASs using a ThT assay. Figure 16 shows the structures of 3'g-AS(b)-original, which contains a 3'-nucleotide sequence of consecutive guanines, and various single-nucleotide-inserted g-ASs containing 3'-nucleotide sequences of consecutive guanines and guanine-rich sequences. Figure 17 shows the results of quantifying G-quadruplex formation in the absence of target mdx RNA using a ThT assay for 3'g-AS(b)-original and single-nucleotide-inserted g-ASs.

[0015] 1. Nucleic Acid Agent 1-1. Overview A first aspect of the present invention is a nucleic acid agent (hereinafter referred to as a "nucleic acid agent of the present invention" or simply a "nucleic acid agent") that can bind to a target nucleic acid molecule containing a guanine repeat sequence consisting of the base sequence GGG. The nucleic acid agent of the present invention comprises a target-binding sequence for hybridizing to a target nucleic acid molecule, and two consecutive guanine sequences and a guanine-rich sequence for forming a G-quadruplex with the guanine repeat sequence consisting of the base sequence GGG in the target nucleic acid molecule. The nucleic acid agent of the present invention reduces the formation of a G-quadruplex structure that multiple nucleic acid agents can form with each other independently of the target nucleic acid molecule, and can efficiently form a G-quadruplex structure with the target nucleic acid molecule.

[0016] 1-2. Definition of Terms As used herein, the term "G-quadruplex (Gq)" or "G-quadruplex structure (Gq structure)" refers to a nucleic acid higher-order structure that can be formed by the interaction of guanine bases on a nucleic acid strand. Typically, a G-quadruplex is formed by the mutual binding of three or more guanine bases on four nucleic acid strands. The four nucleic acid strands that make up a G-quadruplex may be different sequence portions contained within a single-stranded nucleic acid molecule, or may be sequence portions contained separately in multiple nucleic acid molecules. For example, four sets of sequences, each consisting of three guanine bases, present on a single nucleic acid strand can form a G-quadruplex structure on the same nucleic acid strand. Alternatively, four sets of sequences, each consisting of three guanine bases, can be present on two nucleic acids, separated into sets 1 and 3, or sets 2 and 2, to form a G-quadruplex structure between nucleic acid strands. Furthermore, the three or more guanine bases on the four nucleic acid strands that make up the guanine quadruplex may be a sequence of consecutive guanine bases, or a sequence in which one or more bases other than a guanine base are inserted between consecutive guanine bases.

[0017] As used herein, "G-tethered ASO" or "g-AS" refers to a nucleic acid strand comprising a target-binding sequence capable of hybridizing to at least a portion of a target nucleic acid molecule and a sequence capable of forming a G-quadruplex together with a guanine repeat sequence consisting of the base sequence GGG in the target nucleic acid molecule. A g-AS contains at least one set of three guanine bases to form a G-quadruplex together with the guanine repeat sequence of the target nucleic acid molecule. Typically, a g-AS contains two to three sets, depending on the number of guanine repeat sequences contained in the target nucleic acid molecule. The three guanine bases forming a G-quadruplex in a g-AS may be a sequence of consecutive guanine bases, or a sequence in which one or more bases other than a guanine base are inserted between the consecutive guanine bases.

[0018] As used herein, the term "nucleic acid" or "nucleic acid molecule" may refer to a monomeric nucleotide or nucleoside, or may refer to an oligonucleotide consisting of multiple monomers, or, if it is a polymer, to a polynucleotide. "Natural nucleic acid" refers to a nucleic acid that exists in nature. Natural nucleic acids include the natural nucleosides and natural nucleotides described below. "Non-natural nucleic acid" or "artificial nucleic acid" refers to any nucleic acid other than natural nucleic acids. Non-natural nucleic acids or artificial nucleic acids include the non-natural nucleosides and non-natural nucleotides described below.

[0019] As used herein, the term "target nucleic acid molecule" refers to a nucleic acid molecule that is the direct target of the nucleic acid agent or double-stranded nucleic acid complex of the present invention. The target nucleic acid molecule may be either RNA or DNA. RNA may be any RNA synthesized by RNA polymerase. Specific examples include transcription products transcribed from target genes, such as mRNA (including mature mRNA, mRNA precursors, and mRNA without base modifications), non-coding RNA (ncRNA) such as miRNA, long non-coding RNA (lncRNA), viral RNA, and natural antisense RNA. DNA may be, for example, genomic DNA, telomeric DNA, damaged DNA, mitochondrial DNA, and the like. The target nucleic acid molecule preferably contains a guanine repeat sequence consisting of the base sequence GGG. In the target nucleic acid molecule, the guanine repeat sequence may be located, for example, in the 5'UTR, 3'UTR, exon, intron, coding region, translation initiation region, translation termination region, or any other nucleic acid region.

[0020] As used herein, a "target gene" refers to a gene whose transcription or translation product expression level can be suppressed or enhanced, whose transcription or translation product function can be inhibited, or whose steric blocking, splicing switch, RNA editing, exon skipping, or exon inclusion can be induced by the nucleic acid agent or double-stranded nucleic acid complex of the present invention. The type of target gene is not particularly limited as long as it is expressed in vivo, and examples include genes derived from an organism into which the nucleic acid agent or double-stranded nucleic acid complex of the present invention is introduced, such as genes whose expression is increased in various diseases. Examples of target genes include the scavenger receptor B1 (SR-B1) gene, the metastasis-associated lung adenocarcinoma transcript 1 (Malat1) gene, the microtubule-associated protein tau (Mapt) gene, the beta-secretase 1 (BACE1) gene, the DMPK (dystrophia myotonica-protein kinase) gene, and the dystrophin gene. As used herein, the target gene generally contains a guanine repeat sequence consisting of the nucleotide sequence GGG. However, the position of the guanine repeat sequence in the target gene is not particularly limited.

[0021] As used herein, "antisense oligonucleotide (ASO)" or "antisense nucleic acid" refers to a single-stranded oligonucleotide that contains a base sequence capable of hybridizing to (i.e., complementary to) at least a portion of a target nucleic acid molecule and can exert an antisense effect on the target nucleic acid molecule. In the nucleic acid agent or double-stranded nucleic acid complex of the present invention, the target-binding sequence functions as an antisense nucleic acid, and the sequence to which the target-binding sequence hybridizes (hereinafter referred to as the "target sequence") may include a 5' UTR, a 3' UTR, an exon, an intron, an exon / intron junction, an intron / exon junction, a coding region, a translation initiation region, a translation termination region, or any other nucleic acid region. The length of the target sequence is not particularly limited and is typically at least 8 bases long, for example, 10-35 bases, 12-25 bases, 13-20 bases, 14-19 bases, or 15-18 bases, or 13-22 bases, 16-22 bases, or 16-20 bases.

[0022] As used herein, the term "antisense effect" refers to an effect on a target nucleic acid molecule caused by the binding of a nucleic acid agent or double-stranded nucleic acid complex of the present invention to the target nucleic acid molecule, such as regulating the expression or editing of a target transcript. "Regulating the expression or editing of a target transcript" refers to suppression or reduction of target gene expression or target transcript expression level (herein, "target transcript expression level" is often referred to as "target transcript level"), translation inhibition, RNA editing, base editing, splicing control or splicing function modification effects (e.g., splicing switch, exon inclusion, exon skipping, etc.), steric blocking, or transcript degradation. For example, in post-transcriptional inhibition of a target gene, when a nucleic acid agent containing RNA in its target binding sequence is introduced into a cell, the target binding sequence anneals to the mRNA, the transcript of the target gene, forming a partial duplex. This partial duplex acts as a cover to prevent ribosomal translation, thereby inhibiting the expression of the target protein encoded by the target gene at the translational level (steric blocking). Furthermore, when a nucleic acid agent containing DNA in its target binding sequence is introduced into a cell, a partial DNA-RNA heteroduplex is formed. This heteroduplex structure is recognized by RNase H, resulting in degradation of the target gene's mRNA and inhibition of the expression of the protein encoded by the target gene. Furthermore, antisense effects can also be achieved by targeting introns in pre-mRNA. Furthermore, antisense effects can also be achieved by targeting miRNA. In this case, inhibition of the miRNA function can increase the expression of the gene whose expression is normally controlled by the miRNA. In one embodiment, modulation of target transcript expression can be achieved by reducing the amount of the target transcript.

[0023] The antisense effect can be measured, for example, by administering a test nucleic acid compound to a subject (e.g., a mouse) and measuring, for example, several days later (e.g., 2 to 7 days later), the expression level of a target gene or the level (quantity) of a target transcript (e.g., mRNA amount or RNA amount such as microRNA, cDNA amount, protein amount, etc.) whose expression is regulated by the antisense effect provided by the test nucleic acid compound.

[0024] For example, a decrease in the measured expression level of the target gene or the level of the target transcript by at least 10%, at least 20%, at least 25%, at least 30%, or at least 40% compared to a negative control (e.g., vehicle administration) indicates that the test nucleic acid compound can produce an antisense effect (e.g., a reduction in the amount of the target transcript).

[0025] The number, type, and position of non-natural nucleotides in a nucleic acid agent or double-stranded nucleic acid complex can affect the antisense effect, etc. The choice of modification can vary depending on the sequence of the target gene, etc., but those skilled in the art can determine a suitable embodiment by referring to descriptions in prior art literature on antisense methods.

[0026] As used herein, the term "translation product of a target gene" refers to any polypeptide or protein synthesized by translation of a target transcript or a transcription product of a target gene that is the direct target of the nucleic acid agent or double-stranded nucleic acid complex of the present invention.

[0027] As used herein, a "nucleic acid strand" or simply a "strand" refers to two or more nucleosides linked by an internucleoside bond, and may be, for example, an oligonucleotide or a polynucleotide. A nucleic acid strand can be produced in full length or in partial lengths by chemical synthesis, for example, using an automated synthesizer, or by enzymatic processes using polymerases, ligases, or restriction reactions. A nucleic acid strand can include natural and / or non-natural nucleotides.

[0028] "Nucleoside" generally refers to a molecule consisting of a combination of a base and a sugar. The sugar portion of a nucleoside is typically, but not limited to, a pentofuranosyl sugar, specific examples of which include ribose and deoxyribose. The base portion (nucleobase) of a nucleoside is typically a heterocyclic base moiety. Examples include, but are not limited to, adenine, cytosine, guanine, thymine, or uracil, as well as other modified nucleobases (modified bases).

[0029] A "nucleotide" refers to a molecule in which a phosphate group is covalently linked to the sugar portion of a nucleoside. In the case of nucleotides containing a pentofuranosyl sugar, the phosphate group is typically linked to the 2', 3', or 5' hydroxyl group of the sugar.

[0030] An "oligonucleotide" refers to a linear oligomer formed by covalently linking several to several dozen hydroxyl groups in the sugar moieties and phosphate groups of adjacent nucleotides. A "polynucleotide" refers to a linear polymer formed by linking several dozens, preferably several hundred, of nucleotides, more numerous than an oligonucleotide, by such covalent bonds. Within an oligonucleotide or polynucleotide structure, the phosphate groups are generally considered to form internucleoside bonds.

[0031] As used herein, "natural nucleosides" refer to nucleosides that exist in nature. Examples include ribonucleosides consisting of ribose and a base such as adenine, cytosine, guanine, or uracil, and deoxyribonucleosides consisting of deoxyribose and a base such as adenine, cytosine, guanine, or thymine. Ribonucleosides found in RNA and deoxyribonucleosides found in DNA are often referred to herein as "DNA nucleosides" and "RNA nucleosides," respectively.

[0032] As used herein, the term "natural nucleotide" refers to a naturally occurring nucleotide molecule in which a phosphate group is covalently bound to the sugar moiety of the natural nucleoside. Examples include ribonucleotides, which are known as building blocks of RNA and in which a phosphate group is bound to a ribonucleoside, and deoxyribonucleotides, which are known as building blocks of DNA and in which a phosphate group is bound to a deoxyribonucleoside.

[0033] As used herein, the term "non-natural nucleotide" refers to any nucleotide other than a natural nucleotide, including modified nucleotides and nucleotide mimetics. As used herein, "modified nucleotide" refers to a nucleotide having one or more of a modified sugar moiety, a modified internucleoside linkage, and a modified nucleobase. The term "nucleotide mimic" includes structures used to replace nucleosides and linkages at one or more positions in an oligomeric compound. Examples of nucleotide mimetics include nucleic acid mimetics such as peptide nucleic acids. Peptide nucleic acids (PNAs) are nucleic acid mimetics with a backbone in which N-(2-aminoethyl)glycine is linked via an amide bond (-N(H)-C(=O)-) instead of a sugar. Additional nucleic acid mimetics include nucleic acid mimetics with a morpholino backbone (morpholino nucleic acids). Nucleic acid chains containing non-natural oligonucleotides often have desirable properties, such as enhanced cellular uptake, enhanced affinity for nucleic acid targets, increased stability in the presence of nucleases, or increased inhibitory activity. Therefore, they are preferred over natural nucleotides.

[0034] As used herein, the term "unnatural nucleoside" refers to any nucleoside other than a naturally occurring nucleoside. For example, this includes modified nucleosides and nucleoside mimetics. As used herein, the term "modified nucleoside" refers to a nucleoside having a modified sugar moiety and / or a modified nucleobase.

[0035] As used herein, the term "mimetic" refers to functional groups that replace sugars, nucleobases, and / or internucleoside linkages. Generally, mimetics are used in place of sugars or sugar-internucleoside linkage combinations, while maintaining the nucleobases for hybridization to a selected target. As used herein, "nucleoside mimetics" includes structures used to replace sugars, or sugars and bases, at one or more positions in an oligomeric compound, or to replace linkages between monomeric subunits that comprise the oligomeric compound. An "oligomeric compound" refers to a polymer of linked monomeric subunits that is at least capable of hybridizing to a region of a nucleic acid molecule. Nucleoside mimetics include, for example, morpholino, cyclohexenyl, cyclohexyl, tetrahydropyranyl, bicyclic, or tricyclic sugar mimetics, e.g., nucleoside mimetics having non-furanose sugar units.

[0036] "Modified sugar" refers to a sugar having a substitution and / or any change from a natural sugar moiety (i.e., a sugar moiety found in DNA (2'-H) or RNA (2'-OH)), and "sugar modification" refers to a substitution and / or any change from a natural sugar moiety. A nucleic acid strand may optionally include one or more modified nucleosides, including modified sugars. "Sugar-modified nucleoside" refers to a nucleoside having a modified sugar moiety. Such sugar-modified nucleosides may confer enhanced nuclease stability, increased binding affinity, or some other beneficial biological property to a nucleic acid strand. In certain embodiments, a nucleoside includes a chemically modified ribofuranose ring moiety. Examples of chemically modified ribofuranose rings include, but are not limited to, the addition of substituents (including 5' and 2' substituents), bridging of non-geminal ring atoms to form bicyclic nucleic acids (bridged nucleic acids, BNAs), and the modification of ribosyl ring oxygen atoms to S, N(R), or C(R1)(R2) (where R, R1, and R2 are each independently H, C1-C 12 alkyl, or protecting groups), and combinations thereof.

[0037] Examples of sugar-modified nucleosides include, but are not limited to, nucleosides containing 5'-vinyl, 5'-methyl (R or S), 5'-allyl (R or S), 4'-S, 2'-F (2'-fluoro), 2'-OCH (2'-O-Me or 2'-O-methyl), 2'-O-[2-(N-methylcarbamoyl)ethyl] (2'-O-MCE), and 2'-O-methoxyethyl (2'-O-MOE or 2-O(CH)OCH) substituents. The 2'-position substituent may also be an allyl, amino, azido, thio, -O-allyl, -O-C-C 10 alkyl, —OCF, —O(CH)SCH, —O(CH)—ON(R)(R), and O—CH—C(═O)—N(R)(R), where each R and R is independently H or a substituted or unsubstituted C—C 10 The term "2'-modified sugar" refers to a furanosyl sugar modified at the 2'-position. A nucleoside containing a 2'-modified sugar is also referred to as a "2'-modified nucleoside" or a "2'-sugar-modified nucleoside."

[0038] "Bicyclic nucleoside" refers to a modified nucleoside containing a bicyclic sugar moiety. Nucleic acids containing a bicyclic sugar moiety are commonly referred to as bridged nucleic acids (BNAs). Nucleosides containing a bicyclic sugar moiety are sometimes referred to as "bridged nucleosides" or "BNA nucleosides."

[0039] A bicyclic sugar may be a sugar in which the 2'-position carbon atom and the 4'-position carbon atom are bridged by two or more atoms. Examples of bicyclic sugars are known to those skilled in the art, and examples of nucleic acids (BNAs) or BNA nucleosides containing bicyclic sugars include methyleneoxy(4'-CH2-O-2') BNA nucleosides (also known as LNA nucleosides, 2',4'-BNA nucleosides) (e.g., α-L-methyleneoxy(4'-CH2-O-2') BNA nucleosides, β-D ... ') BNA nucleoside), ethyleneoxy (4'-(CH2)2-O-2') BNA nucleoside (also known as ENA nucleoside), β-D-thio (4'-CH2-S-2') BNA nucleoside, aminooxy (4'-CH2-ON(R3)-2') BNA nucleoside, oxyamino (4'-CH2-N(R3)-O-2') BNA nucleoside (2',4'-BNA NC Also known as nucleosides; R=H is 2',4'-BNA NC [NH] nucleoside, R=Me is 2',4'-BNA NC [N-Me] nucleoside), 2',4'-BNA cocNucleosides, 3'-amino-2',4'-BNA nucleosides, 5'-methyl BNA nucleosides, (4'-CH(CH3)-O-2') BNA nucleosides (also known as cEt nucleosides), (4'-CH(CHOCH3)-O-2') BNA nucleosides (also known as cMOE nucleosides), amide BNA nucleosides or (4'-C(O)-N(R)-2') BNA nucleosides (R=H, Me) (also known as AmNA nucleosides; where R=H, AmNA[NH] nucleosides, R=Me) AmNA[N-Me] nucleosides), guanidine BNA nucleosides (also known as GuNA nucleosides (e.g., R=H is GuNA[NH] nucleosides, R=Me is GuNA[N-Me] nucleosides)), amine BNA nucleosides (also known as 2'-Amino-LNA nucleosides) (e.g., 3-(Bis(3-aminopropyl)amino)propanoyl substituted nucleosides), and 2'-O,4'-C-spirocyclopropylene bridged nucleosides (also known as scpBNA nucleosides).

[0040] As used herein, the term "modified internucleoside linkage" refers to an internucleoside linkage that has a substitution or any change from a naturally occurring internucleoside linkage (i.e., a phosphodiester linkage). Modified internucleoside linkages include internucleoside linkages that contain a phosphorus atom and internucleoside linkages that do not contain a phosphorus atom. Representative phosphorus-containing internucleoside linkages include, but are not limited to, phosphodiester linkages, phosphorothioate linkages, phosphorodithioate linkages, phosphotriester linkages, alkylphosphonate linkages, alkylthiophosphonate linkages, methylthiophosphonate linkages, boranophosphate linkages, internucleoside linkages containing cyclic guanidine moieties, and phosphoramidate linkages. A phosphorothioate linkage refers to an internucleoside linkage in which the non-bridging oxygen atom of the phosphodiester bond is replaced with a sulfur atom. Methods for preparing phosphorus-containing and non-phosphorus-containing linkages are well known. Preferably, the modified internucleoside linkage is one that is more resistant to nucleases than naturally occurring internucleoside linkages.

[0041] As used herein, the term "nucleobase" or "base" refers to a base component (heterocyclic moiety) constituting a nucleic acid, and the most commonly known are adenine, guanine, cytosine, thymine, and uracil. Unless otherwise specified, "nucleobase" or "base" herein encompasses both modified and unmodified nucleic acid bases (bases). Therefore, unless otherwise specified, a purine base may be either a modified or unmodified purine base. Furthermore, unless otherwise specified, a pyrimidine base may be either a modified or unmodified pyrimidine base.

[0042] "Modified nucleobase" or "modified base" refers to any nucleobase other than adenine, cytosine, guanine, thymine, or uracil. "Unmodified nucleobase" or "unmodified base" (natural nucleobase) refers to the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U). Examples of modified nucleobases include, but are not limited to, hypoxanthine, 5-methylcytosine, 5-fluorocytosine, 5-bromocytosine, 5-iodocytosine, or N4-methylcytosine; N6-methyladenine or 8-bromoadenine; 2-thiothymine; and N2-methylguanine or 8-bromoguanine.

[0043] As used herein, the term "complementary" refers to a relationship in which nucleic acid bases can form so-called Watson-Crick base pairs (natural base pairs) or non-Watson-Crick base pairs (Hoogsteen base pairs, etc.) through hydrogen bonds. In the present invention, a base sequence having at least 70%, preferably at least 80%, and even more preferably at least 90% (e.g., 95%, 96%, 97%, 98%, or 99% or more) complementarity is acceptable. The complementarity of a base sequence can be determined using a BLAST program or the like. Those skilled in the art can easily determine the conditions (temperature, salt concentration, etc.) under which two strands can anneal or hybridize, taking into account the degree of complementarity between the strands.

[0044] Hybridization conditions may be of various stringent conditions, such as low stringency and high stringency. Low stringency conditions may be conditions of relatively low temperature and high salt concentration, for example, 30°C, 2xSSC, 0.1% SDS. High stringency conditions may be conditions of relatively high temperature and low salt concentration, for example, 65°C, 0.1xSSC, 0.1% SDS. Hybridization stringency can be adjusted by changing conditions such as temperature and salt concentration. Here, 1xSSC contains 150 mM sodium chloride and 15 mM sodium citrate.

[0045] As used herein, the term "subject" refers to a subject to which the nucleic acid agent or pharmaceutical composition of the present invention is applied. Subjects include not only individuals but also organs, tissues, and cells. When the subject is an individual, it can be any animal, including humans. For example, non-human subjects include various livestock, poultry, pets, laboratory animals, etc. The subject may be, but is not limited to, an individual in need of disease treatment or prevention.

[0046] As used herein, the term "plurality" refers to an integer of 2 or more, for example, an integer of 2 to 10, 2 to 7, 2 to 5, 2 to 4, or 2 to 3.

[0047] As used herein, "base identity" refers to the percentage (%) of matching bases in the total number of bases when two nucleic acid sequences are compared and aligned by inserting appropriate gaps into one or both sequences as necessary to maximize the number of matching bases.

[0048] 1-3. Configuration The nucleic acid agent of the present invention comprises a target-binding sequence for hybridizing to a target nucleic acid molecule, and two consecutive guanine sequences and a guanine-rich sequence for forming a G-quadruplex with a guanine repeat sequence consisting of the base sequence GGG in the target nucleic acid molecule. The two consecutive guanine sequences and the guanine-rich sequence of the nucleic acid agent of the present invention and the guanine repeat sequence of the target nucleic acid molecule can form a G-quadruplex structure that is more stable than the G-quadruplex structure that can be formed by multiple nucleic acid agents together.

[0049] In the nucleic acid agent of the present invention, the "target binding sequence" comprises a base sequence complementary to at least a portion of a target nucleic acid molecule and is capable of hybridizing to the target nucleic acid molecule based on the complementary sequence. The base length of the target binding sequence is not particularly limited, but may be at least 8 bases, at least 9 bases, at least 10 bases, at least 11 bases, at least 12 bases, at least 13 bases, at least 14 bases, or at least 15 bases. The base length of the target binding sequence may be 40 bases or less, 35 bases or less, 30 bases or less, 25 bases or less, 24 bases or less, 23 bases or less, 22 bases or less, 21 bases or less, 20 bases or less, 19 bases or less, 18 bases or less, 17 bases or less, or 16 bases or less. Examples of the range of base lengths for the target-binding sequence include 10 to 30 bases, 12 to 30 bases, 12 to 25 bases, 13 to 20 bases, 14 to 19 bases, or 15 to 18 bases, or 13 to 22 bases, 16 to 22 bases, or 16 to 20 bases. The length can be selected based on the balance between the strength of the antisense effect and specificity for the target, among other factors such as cost and synthesis yield. Preferably, the target-binding sequence does not contain the base sequence GGG or the base sequence CCC.

[0050] In addition, the sequence in a target nucleic acid molecule that serves as the target for binding of the target binding sequence of the nucleic acid agent of the present invention (hereinafter referred to as the "target sequence") can be set at any position in the target nucleic acid molecule. For example, when the target nucleic acid molecule is a transcription product, the target sequence may include a 5'UTR, a 3'UTR, an exon, an intron, an exon / intron junction, an intron / exon junction, a coding region, a translation initiation region, a translation termination region, or any other nucleic acid region. The target region is typically at least 8 bases in length, for example, 8 to 40 bases, 10 to 35 bases, 12 to 25 bases, 13 to 20 bases, 14 to 19 bases, or 15 to 18 bases in length.

[0051] As used herein, the term "contiguous guanine sequence" refers to three consecutive guanine bases (i.e., the base sequence GGG), and generally refers to a sequence contained in the nucleic acid agent or double-stranded nucleic acid complex of the present invention. The number of consecutive guanine sequences in the nucleic acid agent of the present invention is not particularly limited as long as it is two or more. For example, the nucleic acid agent of the present invention may contain two consecutive guanine sequences.

[0052] In this specification, the term "guanine repeat sequence" also refers to three consecutive guanine bases (i.e., the base sequence GGG). In this specification, the term "guanine repeat sequence" can be used to refer to either the base sequence GGG contained in the nucleic acid agent or double-stranded nucleic acid complex of the present invention or the base sequence GGG contained in the target nucleic acid molecule. Meanwhile, the above-mentioned "consecutive guanine sequence" is generally used to refer to the base sequence GGG contained in the nucleic acid agent or double-stranded nucleic acid complex of the present invention. For example, when distinguishing between the base sequence GGG contained in the nucleic acid agent or double-stranded nucleic acid complex of the present invention and the base sequence GGG contained in the target nucleic acid molecule, the former base sequence GGG is referred to as a "consecutive guanine sequence," and the latter base sequence GGG is referred to as a "guanine repeat sequence."

[0053] As used herein, the term "guanine-rich sequence" refers to a sequence consisting of three consecutive guanine bases, in which a base other than a guanine base or an abasic site is inserted between two adjacent guanine bases. The inserted base is generally one base, and the inserted abasic site is generally one base long. The number of guanine-rich sequences in the nucleic acid agent of the present invention is not particularly limited as long as it is one or more. For example, the nucleic acid agent of the present invention may contain one guanine-rich sequence.

[0054] In one embodiment, the guanine-rich sequence consists of the base sequence GXGG or GGXG, where "G" represents a guanine base and "X" represents a base other than a guanine base (G base) or a cytosine base (C base), or an abasic site. "X" may be either an unmodified base (natural nucleic acid base) or a modified base.

[0055] In a further embodiment, the guanine-rich sequence consists of the base sequence GXGG or GGXG, where "G" represents a guanine base and "X" is a thymine base (T base), an adenine base (A base), or a uracil base (U base). For example, "X" can be a thymine base (T base) or an adenine base (A base), or a thymine base (T base).

[0056] In the nucleic acid agent of the present invention, the nucleosides constituting the guanine-rich sequence may be natural nucleosides and / or non-natural nucleosides (modified nucleosides). Natural nucleosides may be either DNA nucleosides (deoxyribonucleosides) or RNA nucleosides (ribonucleosides). Furthermore, non-natural nucleotides may contain any of modified sugar moieties, modified internucleoside linkages, and / or modified nucleic acid bases.

[0057] In one embodiment, in a guanine-rich sequence consisting of the base sequence GXGG or GGXG, the nucleoside containing the guanine base indicated by "G" and the nucleoside containing the base indicated by "X" may be a ribonucleoside and a deoxyribonucleoside, respectively, or may be a deoxyribonucleoside and a ribonucleoside, respectively.

[0058] As used herein, the term "abasic site" refers to the structure remaining after the base moiety of a nucleoside is removed by hydrolysis. Abasic sites are also known as apurinic or apyrimidinic sites.

[0059] In the nucleic acid agents of the present invention, the locations of the target-binding sequence, two consecutive guanine sequences, and the guanine-rich sequence are not particularly limited. For example, the two consecutive guanine sequences and the guanine-rich sequence may be located at the 5'-end and / or 3'-end of the target-binding sequence. Furthermore, the locations of the target-binding sequence, two consecutive guanine sequences, and the guanine-rich sequence in the nucleic acid agents of the present invention can be determined based on the location of the target sequence and the guanine repeat sequence consisting of the base sequence GGG in the target nucleic acid molecule. For example, if the target sequence is located at the 5'-end of the guanine repeat sequence in the target nucleic acid molecule, the two consecutive guanine sequences and the guanine-rich sequence can be located at the 3'-end of the target-binding sequence in the nucleic acid agent of the present invention. Conversely, if the target sequence is located at the 3'-end of the guanine repeat sequence in the target nucleic acid molecule, the two consecutive guanine sequences and the guanine-rich sequence can be located at the 5'-end of the target-binding sequence in the nucleic acid agent of the present invention.

[0060] Furthermore, in the nucleic acid agent of the present invention, the arrangement of the two consecutive guanine sequences and the guanine-rich sequence is not particularly limited. For example, the nucleic acid agent of the present invention may include, in order from the 5'-end, a first consecutive guanine sequence, a second consecutive guanine sequence, and a guanine-rich sequence; in order from the 5'-end, a first consecutive guanine sequence, a guanine-rich sequence, and a second consecutive guanine sequence; or, in order from the 5'-end, a guanine-rich sequence, a first consecutive guanine sequence, and a second consecutive guanine sequence.

[0061] In one embodiment, the guanine-rich sequence is located on the 3'-end of the two consecutive guanine sequences. For example, the nucleic acid agent of the present invention comprises, from the 5'-end, a first consecutive guanine sequence, a second consecutive guanine sequence, and a guanine-rich sequence, wherein the guanine-rich sequence consists of the base sequence GXGG, and X in the base sequence represents a base other than G or C bases or an abasic site. Alternatively, the nucleic acid agent of the present invention comprises, from the 5'-end, a first consecutive guanine sequence, a second consecutive guanine sequence, and a guanine-rich sequence, wherein the guanine-rich sequence consists of the base sequence GGXG, and X in the base sequence represents a base other than G or C bases or an abasic site.

[0062] In another embodiment, the guanine-rich sequence is located between two consecutive guanine sequences. For example, the nucleic acid agent of the present invention comprises, from the 5'-end, a first consecutive guanine sequence, a guanine-rich sequence, and a second consecutive guanine sequence, wherein the guanine-rich sequence consists of the base sequence GXGG, and X in the base sequence represents a base other than G or C bases or an abasic site. Alternatively, the nucleic acid agent of the present invention comprises, from the 5'-end, a first consecutive guanine sequence, a guanine-rich sequence, and a second consecutive guanine sequence, wherein the guanine-rich sequence consists of the base sequence GGXG, and X in the base sequence represents a base other than G or C bases or an abasic site.

[0063] In yet another embodiment, the guanine-rich sequence is located on the 5'-end side of the two consecutive guanine sequences. For example, the nucleic acid agent of the present invention comprises, from the 5'-end side, a guanine-rich sequence, a first consecutive guanine sequence, and a second consecutive guanine sequence, wherein the guanine-rich sequence consists of the base sequence GXGG, and X in the base sequence represents a base other than G or C bases or an abasic site. Alternatively, the nucleic acid agent of the present invention comprises, from the 5'-end side, a guanine-rich sequence, a first consecutive guanine sequence, and a second consecutive guanine sequence, wherein the guanine-rich sequence consists of the base sequence GGXG, and X in the base sequence represents a base other than G or C bases or an abasic site.

[0064] In one embodiment of the nucleic acid agent of the present invention, the two consecutive guanine sequences and the guanine-rich sequence are located on the 5'-end side of the target binding sequence, and (i) the guanine-rich sequence is located on the 5'-end side of the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG, (ii) the guanine-rich sequence is located between the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG, or (iii) the guanine-rich sequence is located on the 3'-end side of the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GGXG, wherein X in the base sequence represents a base other than a G base or a C base, or an abasic site.

[0065] In a further embodiment of the nucleic acid agent of the present invention, the two consecutive guanine sequences and the guanine-rich sequence are located on the 5' end side of the target binding sequence, the guanine-rich sequence is located between the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG, where X in the base sequence represents a base other than a G base or a C base, or an abasic site.

[0066] In a further embodiment of the nucleic acid agent of the present invention, the two consecutive guanine sequences and the guanine-rich sequence are located on the 5' end side of the target binding sequence, the guanine-rich sequence is located between the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG, where X in the base sequence represents a base other than a G base or a C base, or an abasic site.

[0067] In one embodiment of the nucleic acid agent of the present invention, the two consecutive guanine sequences and the guanine-rich sequence are located on the 3'-end side of the target binding sequence, and (i) the guanine-rich sequence is located on the 5'-end side of the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GGXG, (ii) the guanine-rich sequence is located between the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG, or (iii) the guanine-rich sequence is located on the 3'-end side of the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG, wherein X in the base sequence represents a base other than a G base or a C base, or an abasic site.

[0068] In a further embodiment of the nucleic acid agent of the present invention, the two consecutive guanine sequences and the guanine-rich sequence are located on the 3'-end side of the target binding sequence, the guanine-rich sequence is located between the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG, where X in the base sequence represents a base other than a G base or a C base, or an abasic site.

[0069] In a further embodiment of the nucleic acid agent of the present invention, the two consecutive guanine sequences and the guanine-rich sequence are located on the 3' end of the target binding sequence, the guanine-rich sequence is located between the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GGXG, where X in the base sequence represents a base other than a G base or a C base, or an abasic site.

[0070] In one embodiment, the nucleic acid agent of the present invention includes a linker sequence between two adjacent sequences of the two consecutive guanine sequences and the guanine-rich sequence, the linker sequence being composed of one or more bases other than G or C. The type of nucleic acid constituting the linker sequence is not particularly limited, and may be composed of unmodified bases and / or modified bases other than G or C, for example, T bases, A bases, and / or U bases. The base length of the linker sequence is not particularly limited, and may be, for example, 1 to 30 bases, 2 to 20 bases, 3 to 10 bases, or 4 to 6 bases, or may be, for example, 1 or 2 bases.

[0071] In one embodiment, the nucleic acid agent of the present invention includes a spacer sequence or spacer molecule between the two consecutive guanine sequences and the guanine-rich sequence and the target binding sequence. The nucleic acid constituting the spacer sequence may consist of, for example, one nucleoside or 1-10 bases linked by internucleoside bonds, for example, 2-9, 3-8, 4-7, or 5-6 nucleosides. The nucleosides may include natural and / or non-natural nucleosides. The type of nucleic acid is not particularly limited, and may be, for example, a peptide nucleic acid. The spacer molecule is not particularly limited, and may be, for example, a peptide chain, a polyether chain, and / or a hydrocarbon chain.

[0072] In another embodiment, the nucleic acid agent of the present invention does not include a spacer sequence between the two consecutive guanine sequences and the guanine-rich sequence and the target binding sequence, in which the two consecutive guanine sequences and the guanine-rich sequence and the target binding sequence are linked via one internucleoside linkage.

[0073] In one embodiment, the nucleic acid agent of the present invention does not contain the base sequence GGG and / or does not contain the base sequence CCC other than the two consecutive guanine sequences described above.

[0074] In a further embodiment, the nucleic acid agent of the present invention does not contain the base sequence GGXG or GXGG (where X is a base other than a G base or a C base, or an abasic site) other than the above-mentioned guanine-rich sequence.

[0075] The base length of the nucleic acid agent of the present invention is not particularly limited. For example, the base length of the nucleic acid agent may be at least 22, 25, 30, 35, 40, 50, or 60 bases, and / or may be 500, 200, 100, 50, 40, 35, 30, or 25 bases or less. Exemplary ranges include 22 to 300 bases, 30 to 100 bases, or 40 to 60 bases.

[0076] In one embodiment, nucleic acid agents of the present invention include natural and / or unnatural nucleosides. For example, nucleic acid agents of the present invention can include unnatural nucleosides in the target binding sequence and / or can include one or more unnatural nucleosides at the 5'-end and / or 3'-end of the nucleic acid agent. The unnatural nucleosides can be 2'-modified nucleosides, 5'-modified nucleosides, and / or bridged nucleosides.

[0077] In a further embodiment, the nucleic acid agent of the present invention comprises or consists of a morpholino nucleic acid. For example, the nucleic acid agent of the present invention can comprise a morpholino nucleic acid in the target binding sequence, or can comprise a target binding sequence consisting of a morpholino nucleic acid.

[0078] In one embodiment, all or some of the internucleoside linkages of the nucleic acid agent of the present invention may be modified internucleoside linkages. For example, at least one, at least two, or at least three internucleoside linkages from the ends (5' end, 3' end, or both ends) of the nucleic acid agent may be modified internucleoside linkages. In one embodiment, all or some of the internucleoside linkages of the nucleic acid agent may be modified internucleoside linkages. The modified internucleoside linkages may be phosphorothioate linkages.

[0079] In one embodiment, the target nucleic acid molecule is RNA or DNA. The RNA may be mRNA or a precursor thereof, non-coding RNA, or viral RNA.

[0080] When the nucleic acid agent of the present invention acts on a target nucleic acid molecule, a loop structure can be formed in the region between the guanine repeat sequence involved in the formation of a G-quadruplex structure of the target nucleic acid molecule and the target sequence to which the target binding sequence hybridizes (herein referred to as a "loop-forming sequence"). The base length of the loop-forming sequence is not particularly limited and may be, for example, 1 to 3,000 bases, 1 to 2,000 bases, 10 to 1,000 bases, 50 to 500 bases, or 100 to 300 bases, such as 1 to 500 bases.

[0081] 1-4. Method for Producing Nucleic Acid Agents Those skilled in the art can produce the nucleic acid agents of the present invention by appropriately selecting known methods. Although not limited thereto, the process typically begins with designing and producing the nucleic acid strands that constitute the nucleic acid agent. Next, based on the designed base sequence information, each nucleic acid strand can be synthesized using a commercially available automated nucleic acid synthesizer, for example, from GE Healthcare, Thermo Fisher Scientific, Beckman Coulter, or the like. The resulting oligonucleotides can then be purified using a reverse-phase column or the like. Alternatively, nucleic acid strands can be ordered and obtained from various manufacturers (e.g., Gene Design, Inc.) by specifying the base sequence and modification site and type.

[0082] 1-5. Effects The nucleic acid agents of the present invention can form stable G-quadruplex structures with target nucleic acid molecules. In target nucleic acid molecules, the region between the guanine repeat sequence involved in G-quadruplex formation and the target sequence hybridized with the target-binding sequence can form a loop structure (Figure 1). The nucleic acid agents of the present invention can block the function of various RNA modifying factors, such as miRNAs, RNA-binding proteins, translation factors, and splicing factors, that target sequences contained in the loop structure through steric hindrance, thereby inducing steric blocking, exon skipping, or exon inclusion (Figure 2). Furthermore, the nucleic acid agents of the present invention can suppress mRNA translation and inhibit or inhibit reverse transcription of viral RNA.

[0083] The nucleic acid agents of the present invention suppress the formation of self-G-quadruplex structures that can be formed between nucleic acid agents independently of a target nucleic acid molecule, while maintaining the efficiency of forming a targeted G-quadruplex structure with a target nucleic acid molecule. As a result, the two consecutive guanine sequences and the guanine-rich sequence contained in the nucleic acid agents of the present invention and the guanine repeat sequence contained in the target nucleic acid molecule can form a targeted G-quadruplex structure that is more stable than the self-G-quadruplex structures that can be formed between multiple nucleic acid agents. As a result, the nucleic acid agents of the present invention can efficiently induce loop structures in the target nucleic acid molecule, thereby enhancing their effectiveness against the target nucleic acid molecule (Figure 9).

[0084] It has been reported that in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), GGGGCC repeat sequences that can form G-quadruplex structures are expanded in the C9ORF72 locus, and that RNA transcribed from this locus can exert toxicity through interaction with RNA-binding proteins (Donnelly, CJ, et al., Neuron, 2013, 80(2): 415-428.). The nucleic acid agent of the present invention selectively suppresses the formation of self-G-quadruplex structures, thereby reducing the toxicity that may be caused by consecutive guanine sequences.

[0085] The present invention provides a method for treating and / or preventing a disease, comprising administering any of the above-described nucleic acid agents to a subject such as a human. The present invention also provides any of the above-described nucleic acid agents for use in treating and / or preventing a disease in a subject such as a human. The present invention also provides any of the above-described nucleic acid agents for use in the manufacture of a medicament for treating and / or preventing a disease.

[0086] 2. Double-Stranded Nucleic Acid Complex 2-1. Overview A second aspect of the present invention is a double-stranded nucleic acid complex. The double-stranded nucleic acid complex of the present invention comprises a first nucleic acid strand and a second nucleic acid strand, and the first nucleic acid strand is composed of the nucleic acid agent described in the first aspect. In the double-stranded nucleic acid complex of the present invention, the first nucleic acid strand and the second nucleic acid strand can hybridize to form a duplex, and the second nucleic acid strand can assist in the delivery of the first nucleic acid strand, thereby exhibiting high efficacy.

[0087] 2-2. Configuration The double-stranded nucleic acid complex of the present invention comprises a first nucleic acid strand and a second nucleic acid strand. The first nucleic acid strand in the double-stranded nucleic acid complex of the present invention can be selected from any of the embodiments of the nucleic acid agent of the first aspect, and therefore will not be described here.

[0088] In the double-stranded nucleic acid complex of the present invention, the second nucleic acid strand is a nucleic acid molecule containing a base sequence complementary to that of the first nucleic acid strand. In the double-stranded nucleic acid complex of the present invention, the second nucleic acid strand is annealed to the first nucleic acid strand through hydrogen bonds of complementary base pairs. Examples of this embodiment include heteroduplex oligonucleotides (HDOs) disclosed in WO 2013 / 089283, Nishina K, et al., Nature Communication, 2015, 6:7969, and Asami Y, et al., Drug Discoveries & Therapeutics. 2016; 10(5):256-262.

[0089] In one embodiment, the second nucleic acid strand may include ribonucleosides, deoxyribonucleosides, and / or modified nucleosides.

[0090] In further embodiments, all nucleosides in the region of the second nucleic acid strand that consists of a base sequence complementary to the target binding region of the first nucleic acid strand may be (a) deoxyribonucleosides; (b) deoxyribonucleosides and ribonucleosides; (c) deoxyribonucleosides and 2'-modified nucleosides; (d) ribonucleosides and 2'-modified nucleosides; or (e) deoxyribonucleosides, ribonucleosides, and 2'-modified nucleosides.

[0091] In one embodiment, the second nucleic acid strand comprises a region comprising at least two consecutive ribonucleosides and / or deoxyribonucleosides complementary to at least two consecutive deoxyribonucleosides in the target binding region of the first nucleic acid strand. For example, the second nucleic acid strand may comprise a region comprising at least three or at least four consecutive ribonucleosides and / or deoxyribonucleosides complementary to at least three or at least four consecutive deoxyribonucleosides in the target binding region of the first nucleic acid strand. Here, the number of consecutive deoxyribonucleosides in the target binding region of the first nucleic acid strand and the number of consecutive ribonucleosides and / or deoxyribonucleosides complementary to those consecutive deoxyribonucleosides in the second nucleic acid strand may be the same or different. For example, the number of consecutive deoxyribonucleosides may be at least four, and the number of consecutive ribonucleosides and / or deoxyribonucleosides may be at least three.

[0092] In a further embodiment, the second nucleic acid strand comprises a bridged nucleoside. The bridged nucleoside is an LNA nucleoside, an ENA nucleoside, or a BNA nucleoside. NC It may also be a nucleoside.

[0093] The internucleoside linkages in the second nucleic acid strand may be naturally occurring internucleoside linkages and / or modified internucleoside linkages. Preferably, at least one, at least two, or at least three internucleoside linkages from the ends (5' end, 3' end, or both ends) of the second nucleic acid strand are modified internucleoside linkages. In one embodiment, all or part of the internucleoside linkages in the second nucleic acid strand may be modified internucleoside linkages. In one embodiment, the second nucleic acid strand may contain modified internucleoside linkages in a region comprising a base sequence complementary to the target binding region of the first nucleic acid strand. The modified internucleoside linkages may be phosphorothioate linkages.

[0094] In further embodiments, the second nucleic acid strand can include 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides). The number of 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides) in the second nucleic acid strand is not limited. For example, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%, or even 100% of the total number of nucleosides in the second nucleic acid strand can be 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides). In one embodiment, all of the nucleosides in the second nucleic acid strand are 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides).

[0095] In further embodiments, the second nucleic acid strand can include one or two or more contiguous 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides) at the 5'-terminus and / or one or two or more contiguous 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides) at the 3'-terminus. The number of 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides) at the 5'-terminus and / or 3'-terminus is not limited. For example, the second nucleic acid strand can include one or two, three, four, five, six, or seven 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides) at the 5'-terminus and / or one or two, three, four, five, six, or seven 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides) at the 3'-terminus.

[0096] The second nucleic acid strand may also contain 1 to 7 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides) at positions other than the one or two or more consecutive 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides) located at the 5'-end and / or 3'-end described above.

[0097] In any of the above embodiments, the types of nucleosides other than 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides) in the second nucleic acid strand are not particularly limited. For example, in the second nucleic acid strand, all nucleosides other than 2'-modified nucleosides (e.g., 2'-O-methoxyethyl-modified nucleosides) may be deoxyribonucleosides.

[0098] In one embodiment, the second nucleic acid strand may comprise modified nucleobases, the number of which is not limited, and may be, for example, at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6.

[0099] In one embodiment, the second nucleic acid strand may further include at least one overhang region located at one or both of the 5' and 3' ends of the complementary region. An example of this embodiment is described in International Publication No. 2018 / 062510. An "overhang region" refers to a region adjacent to a complementary region, where, when the first and second nucleic acid strands anneal to form a double-stranded structure, the 5' end of the second nucleic acid strand extends beyond the 3' end of the first nucleic acid strand and / or the 3' end of the second nucleic acid strand extends beyond the 5' end of the first nucleic acid strand, i.e., a nucleotide region in the second nucleic acid strand that protrudes from the double-stranded structure. The overhang region in the second nucleic acid strand may be located at either the 5' end or the 3' end of the complementary region. The overhang region in the second nucleic acid strand may be located at either the 5' end or the 3' end of the complementary region. The length of the overhang region is not particularly limited, and may be, for example, 1 to 30 bases long, 2 to 25 bases long, 5 to 20 bases long, or 8 to 15 bases long.

[0100] In one embodiment, a functional moiety may be bound to the first nucleic acid strand and / or the second nucleic acid strand, for example, the second nucleic acid strand. The bond between the first nucleic acid strand and / or the second nucleic acid strand and the functional moiety may be a direct bond or an indirect bond via another substance, but in one embodiment, the first nucleic acid strand and / or the second nucleic acid strand and the functional moiety are preferably directly bound to each other via a covalent bond, an ionic bond, a hydrogen bond, or the like, and a covalent bond is more preferred from the viewpoint of obtaining a more stable bond.

[0101] In one embodiment, the structure of the "functional moiety" is not particularly limited and confers a desired function to the double-stranded nucleic acid complex to which it is bound. Desired functions include labeling, purification, and target delivery. Examples of moieties that confer labeling include compounds such as fluorescent proteins and luciferase. Examples of moieties that confer purification include compounds such as biotin, avidin, His-tag peptide, GST-tag peptide, and FLAG-tag peptide. Furthermore, from the viewpoint of highly specific and efficient delivery of the first nucleic acid strand to a target site and highly effective suppression of target gene expression by the nucleic acid, it is preferable that a molecule having the activity of delivering the double-stranded nucleic acid complex to a target site be bound as a functional moiety to the first nucleic acid strand and / or the second nucleic acid strand in certain embodiments. Examples of moieties that confer target delivery include lipids, antibodies, aptamers, and ligands for specific receptors.

[0102] In one embodiment, the first nucleic acid strand and / or the second nucleic acid strand, for example, the second nucleic acid strand, is bound to a lipid. Examples of the lipid include, but are not limited to, tocopherol, cholesterol, fatty acids, phospholipids and their analogs; folic acid, vitamin C, vitamin B1, vitamin B2; estradiol, androstane and their analogs; steroids and their analogs; ligands for LDLR, SRBI, or LRP1 / 2; FK-506, and cyclosporine; and lipids described in PCT / JP2019 / 12077 and PCT / JP2019 / 10392. The lipid may be tocopherol or an analog thereof and / or cholesterol or an analog thereof, substituted or unsubstituted C 1~30 an alkyl group of the formula 2~30 or a substituted or unsubstituted alkenyl group of 1~30For example, the lipid may be selected from the group consisting of cholesterol or an analog thereof, tocopherol or an analog thereof, folic acid, phosphatidylethanolamine, and a substituted or unsubstituted hydrocarbon group having 16 to 30 carbon atoms. In one embodiment, the second nucleic acid strand may be bound to tocopherol or cholesterol or an analog thereof.

[0103] The functional moiety may be linked to the 5'-end, the 3'-end, or both ends of the first and / or second nucleic acid strand. Alternatively, the functional moiety may be linked to an internal nucleotide of the first and / or second nucleic acid strand. The first and / or second nucleic acid strand may contain two or more functional moieties, such as lipids, which may be linked to multiple positions on the first and / or second nucleic acid strand and / or may be linked as a group to a single position on the first and / or second nucleic acid strand. One functional moiety may be linked to the 5'-end and one to the 3'-end of the first and / or second nucleic acid strand.

[0104] The bond between the first and / or second nucleic acid strand and the functional moiety may be a direct bond or an indirect bond mediated by another substance. However, in certain embodiments, the functional moiety is preferably directly bonded to the first and / or second nucleic acid strand via a covalent bond, ionic bond, hydrogen bond, etc., and a covalent bond is more preferred in view of obtaining a more stable bond.

[0105] The functional moiety may also be linked to the first nucleic acid strand and / or the second nucleic acid strand via a cleavable or noncleavable linker. In this case, the first nucleic acid strand and the second nucleic acid strand may be linked via a linker to form a single strand. However, since the functional region in this case has the same structure as in the double-stranded nucleic acid complex, this specification also encompasses such single-stranded nucleic acids as an embodiment of the double-stranded nucleic acid complex of the present invention. The linker may be any polymer. Examples include polynucleotides, polypeptides, and alkylenes. Specifically, it may be composed of natural nucleotides such as DNA and RNA, or unnatural nucleotides such as peptide nucleic acids and morpholino nucleic acids. When the linker is composed of a nucleic acid, the chain length of the linker may be at least one base, for example, 3 to 10 bases or 4 to 6 bases. A chain length of 4 bases is preferred. In this case, the linker may take the form of a hinge (hairpin loop). The linker can be located on either the 5' or 3' side of the first nucleic acid strand. For example, when the second nucleic acid strand is bound to the 5' side of the first nucleic acid strand, the 5' end of the first nucleic acid strand and the 3' end of the second nucleic acid strand are linked via the linker.

[0106] "Cleavable linker" refers to a linking group that is cleaved under physiological conditions, e.g., within a cell or an animal (e.g., within a human body). In certain embodiments, the cleavable linker is selectively cleaved by an endogenous enzyme, such as a nuclease. Cleavable linkers include amide, ester, phosphodiester or both esters, phosphate ester, carbamate, and disulfide bonds, as well as natural DNA linkers.

[0107] The term "non-cleavable linker" refers to a linker that is not cleaved under physiological conditions, for example, within a cell or an animal body (e.g., within the human body). Examples of non-cleavable linkers include, but are not limited to, linkers consisting of phosphorothioate bonds, and modified or unmodified deoxyribonucleosides or modified or unmodified ribonucleosides linked by phosphorothioate bonds. When the linker is a nucleic acid such as DNA or an oligonucleotide, the chain length is not particularly limited, but may typically be 2 to 20 bases, 3 to 10 bases, or 4 to 6 bases.

[0108] A specific example of the linker is a linker represented by the following formula (I):

[0109] (In the formula, L 2 is a substituted or unsubstituted C1 to C 12 (e.g., propylene, hexylene, dodecylene), a substituted or unsubstituted C3 to C8 cycloalkylene group (e.g., cyclohexylene), —(CH2)2-O—(CH2)2-O—(CH2)2-O—(CH2)2-O—(CH2)3-, —(CH2)2-O—(CH2)2-O—(CH2)2-O—(CH2)2-O—(CH2)3-, or CH(CH2-OH)—CH2-O—(CH2)2-O—(CH2)2-O—(CH2)2-O—(CH2)2-O—(CH2)3-; L 3 represents -NH- or a bond, and L 4 is a substituted or unsubstituted C1 to C 12 Alkylene groups (e.g., ethylene, pentylene, heptylene, undecylene), substituted or unsubstituted C 3~8 Cycloalkylene groups (e.g., cyclohexylene), -(CH2)2-[O-(CH2)2] m - or a bond, where m is an integer from 1 to 25; L 5 represents -NH-(C=O)-, -(C=O)-, or a bond (wherein the substitution is preferably made by a halogen atom).

[0110] In one embodiment, the linker of formula (I) is L 2is an unsubstituted C3 to C6 alkylene group (e.g., propylene, hexylene), —(CH2)2-O—(CH2)2-O—(CH2)2-O—(CH2)3-, or —(CH2)2-O—(CH2)2-O—(CH2)2-O—(CH2)2-O—(CH2)2-O—(CH2)3-, and L 3 is -NH-, and L 4 and L 5 is a bond.

[0111] In the double-stranded nucleic acid complex, the base length of the second nucleic acid strand is not particularly limited, but may be at least 8 bases, at least 9 bases, at least 10 bases, at least 11 bases, at least 12 bases, at least 13 bases, at least 14 bases, or at least 15 bases. The base length of the second nucleic acid strand may be 40 bases or less, 35 bases or less, 30 bases or less, 25 bases or less, 24 bases or less, 23 bases or less, 22 bases or less, 21 bases or less, 20 bases or less, 19 bases or less, 18 bases or less, 17 bases or less, or 16 bases or less. The first and second nucleic acid strands may be the same length or different lengths (e.g., one of them may be 1 to 3 bases shorter or longer).

[0112] In one embodiment, the second nucleic acid strand may contain non-complementary bases and / or one or more inserted and / or deleted bases relative to the first nucleic acid strand. The number of non-complementary bases in the second nucleic acid strand is not limited, and may be, for example, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2. The sequence consisting of non-complementary bases may form a bulge structure, as described below. The length of the inserted sequence in the second nucleic acid strand is not limited, and may be, for example, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2. The inserted sequence may form a bulge structure, as described below. The length of the deleted consecutive bases in the second nucleic acid strand is not limited, and may be, for example, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2. The second nucleic acid strand may contain a bulge structure, as described below, at the deletion position.

[0113] In one embodiment, the second nucleic acid strand contains at least one bulge structure consisting of a base sequence non-complementary to the first nucleic acid strand. As used herein, the term "bulge structure" refers to a portion of a nucleic acid in one of the nucleic acid strands constituting the double strand in a double-stranded nucleic acid complex, where the nucleic acid protrudes from the double-stranded structure without base pairing. The base length of the bulge structure is not limited. For example, it may be 1 to 50 bases long, 1 to 40 bases long, 1 to 30 bases long, 1 to 20 bases long, or 1 to 15 bases long, preferably 1 to 10 bases long.

[0114] 2-3. Effects The first nucleic acid strand of the double-stranded nucleic acid complex of the present invention can form a stable G-quadruplex structure with a target nucleic acid molecule.

[0115] The present invention also provides a method for treating and / or preventing a disease, comprising administering the double-stranded nucleic acid complex of the present invention to a subject such as a human. The present invention also provides any of the double-stranded nucleic acid complexes described above for use in treating and / or preventing a disease in a subject such as a human. The present invention also provides any of the double-stranded nucleic acid complexes described above for use in the manufacture of a medicament for treating and / or preventing a disease.

[0116] 3. Pharmaceutical Composition 3-1. Overview The third aspect of the present invention is a pharmaceutical composition. The pharmaceutical composition of the present invention contains the nucleic acid agent or double-stranded nucleic acid complex described herein as an active ingredient and can be used to treat diseases.

[0117] 3-2. Composition (Active Ingredient) The pharmaceutical composition of the present invention comprises at least one nucleic acid molecule and / or double-stranded nucleic acid complex described herein. For example, the pharmaceutical composition of the present invention can comprise one to four or two to three, for example one, type of nucleic acid molecule and / or double-stranded nucleic acid complex described herein.

[0118] The amount (content) of nucleic acid molecules or double-stranded nucleic acid complexes contained in a pharmaceutical composition varies depending on the type of nucleic acid molecule or double-stranded nucleic acid complex, the site of delivery, the dosage form of the pharmaceutical composition, the dosage of the pharmaceutical composition, and the type of carrier (described below). Therefore, it can be determined appropriately taking into account each condition. Typically, a single dose of pharmaceutical composition is adjusted to contain an effective amount of nucleic acid molecules or double-stranded nucleic acid complexes. The term "effective amount" refers to the amount of nucleic acid molecules or double-stranded nucleic acid complexes necessary to function as active ingredients. An "effective amount" may be an amount that causes little or no harmful side effects to the organism to which it is applied. This effective amount may vary depending on various conditions, such as subject information, administration route, and administration frequency. Ultimately, it is determined by the judgment of a physician, veterinarian, or pharmacist. "Subject information" refers to various individual information about the organism to which the pharmaceutical composition is applied. For example, if the subject is a human, this information includes age, weight, sex, diet, health condition, disease progression and severity, drug sensitivity, and the presence or absence of concomitant medications.

[0119] The pharmaceutical composition of the present invention may consist solely of the nucleic acid molecule or double-stranded nucleic acid complex described herein, or may further contain auxiliary components such as a carrier in addition to the nucleic acid molecule or double-stranded nucleic acid complex described herein.

[0120] (Carrier) The pharmaceutical composition of the present invention can contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to an additive commonly used in the pharmaceutical technology field. Examples include solvents, vegetable oils, bases, emulsifiers, suspending agents, surfactants, pH adjusters, stabilizers, flavors, fragrances, excipients, vehicles, preservatives, binders, diluents, isotonicity adjusters, sedatives, bulking agents, disintegrants, buffers, coating agents, lubricants, colorants, sweeteners, thickeners, flavoring agents, solubilizers, and other additives.

[0121] The solvent may be, for example, water or any other pharmaceutically acceptable aqueous solution, or a pharmaceutically acceptable organic solvent. Examples of aqueous solutions include physiological saline, isotonic solutions containing glucose or other adjuvants, phosphate buffer, and sodium acetate buffer. Examples of adjuvants include D-sorbitol, D-mannose, D-mannitol, sodium chloride, low-concentration nonionic surfactants, polyoxyethylene sorbitan fatty acid esters, etc.

[0122] The above-mentioned carriers are used to avoid or suppress the degradation of the active ingredient, the nucleic acid molecule or double-stranded nucleic acid complex, by enzymes and the like in the body, as well as to facilitate formulation and administration methods and maintain the dosage form and medicinal efficacy, and may be used appropriately as needed.

[0123] (Dosage Form) The dosage form of the pharmaceutical composition of the present invention is not particularly limited as long as it is a form that can exert the pharmacological effect of the active ingredient in vivo without inactivating the active ingredient, the nucleic acid molecule or double-stranded nucleic acid complex described in this specification, by degradation or the like.

[0124] The specific dosage form varies depending on the administration method and / or formulation conditions. The administration method can be roughly divided into parenteral administration and oral administration, and therefore, a dosage form suitable for each administration method may be used.

[0125] If the administration method is parenteral administration, the preferred dosage form is a liquid that can be administered directly to the target site or systemically via the circulatory system. Examples of liquids include injections. Injections can be formulated by appropriately combining the above-mentioned excipients, elixirs, emulsifiers, suspending agents, surfactants, stabilizers, pH adjusters, etc., and mixing them in a unit dosage form required for generally accepted pharmaceutical practice. Other forms include ointments, plasters, cataplasms, transdermal agents, lotions, inhalants, aerosols, eye drops, and suppositories.

[0126] When the administration method is oral administration, preferred dosage forms include solids (including tablets, capsules, drops, and lozenges), granules, powders, powders, and liquids (including oral solutions, emulsions, and syrups). If a solid is used, it can be made into a dosage form coated with a coating known in the art, such as sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets, double tablets, and multi-layer tablets, as needed.

[0127] The specific shape and size of each of the above dosage forms are not particularly limited as long as they are within the range of dosage forms known in the art. The pharmaceutical composition of the present invention may be formulated according to a conventional method in the art.

[0128] (Target Diseases) The pharmaceutical composition of the present invention can be used for the treatment or prevention of any disease. The type of disease is not particularly limited, and may be, for example, a neuromuscular disease, an infectious disease, an inflammatory disease, cancer, an immune disease, an ischemic disease, or a metabolic disease. The neuromuscular disease may be, for example, a neurological disease, a muscle disease, a neuromuscular junction disease, a neurodegenerative disease, or a muscular dystrophy. The neurological disease may be a central nervous system disease or a peripheral nervous system disease. Examples of central nervous system diseases include brain tumors, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, brain tumors, demyelinating diseases, and neuropathic pain. The infectious disease may be a viral infection, such as human immunodeficiency virus (HIV) infection, acquired immunodeficiency syndrome (AIDS), or hepatitis B virus (HBV) infection. The cancer may be adenocarcinoma, squamous cell carcinoma, small cell carcinoma, or large cell carcinoma, and examples thereof include malignant melanoma, oral cancer, laryngeal cancer, pharyngeal cancer, thyroid cancer, lung cancer, breast cancer, esophageal cancer, gastric cancer, colorectal cancer (including colon cancer and rectal cancer), small intestine cancer, bladder cancer, prostate cancer, testicular cancer, uterine cancer, cervical cancer, endometrial cancer, ovarian cancer, kidney cancer, liver cancer, pancreatic cancer, biliary tract cancer (including gallbladder cancer and bile duct cancer), brain tumor, head and neck cancer, mesothelioma, osteosarcoma, soft tissue sarcoma, glioma, neuroblastoma, and other childhood tumors, and blood cancer. Examples of blood cancer include leukemia (e.g., B-cell leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia), lymphoma (e.g., non-Hodgkin's lymphoma), and myeloma (e.g., multiple myeloma). The ischemic disease may be either a chronic ischemic disease or an acute ischemic disease, such as cerebral infarction, myocardial infarction, or arteriosclerosis obliterans of the lower limbs.Further examples of diseases include muscular dystrophies (such as Duchenne muscular dystrophy, myotonic dystrophy type 1 (DM1), Fukuyama muscular dystrophy, facioscapulohumeral muscular dystrophy, and limb-girdle muscular dystrophy), congenital myopathies, primary age-related tauopathy (PART), progressive supranuclear palsy (PSP), corticobasal degeneration / corticobasal syndrome (CBD), Pick's disease, frontotemporal dementia, neuronal inclusion body disease, spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), hereditary spinocerebellar degeneration (SCA), multiple system atrophy, hereditary spastic paraplegia, multiple sclerosis, cerebral infarction, epilepsy, and encephalitis.

[0129] (Dosage Form and Dosage) In the present specification, there are no particular limitations on the preferred administration form of the pharmaceutical composition. Administration may be systemic or local. The administration route may be oral or parenteral. Specific examples of parenteral administration include intravenous administration, intraarterial administration, administration by blood transfusion, intraperitoneal administration, intraventricular administration, intrathecal administration, intraocular administration, intramuscular administration, subcutaneous administration (including implantable continuous subcutaneous administration), intradermal administration, intravesical administration, intravaginal administration, rectal administration, nasal administration, inhalation or nasal instillation, and tracheal / bronchial administration. When the target site of application of the present invention is the brain, intraventricular administration or intrathecal administration is preferred. For example, administration may be intravenous administration, intratumoral administration, hepatic artery injection, splenic subcapsular injection, subcutaneous administration, intraventricular administration, or intrathecal administration. Intrathecal administration may be posterior fossa puncture or lumbar puncture.

[0130] When the pharmaceutical composition is administered or ingested, the dosage or intake may be, for example, such that the nucleic acid agent or double-stranded nucleic acid complex contained therein is 0.00001 mg / kg / day to 10,000 mg / kg / day, or 0.001 mg / kg / day to 100 mg / kg / day. The pharmaceutical composition may be administered in a single dose or multiple doses. In the case of multiple doses, the composition may be administered daily or at appropriate intervals (e.g., at intervals of 1 day, 2 days, 3 days, 1 week, 2 weeks, or 1 month), for example, 2 to 20 times. The single dose of the nucleic acid agent or double-stranded nucleic acid complex can be, for example, 0.001 mg / kg or more, 0.005 mg / kg or more, 0.01 mg / kg or more, 0.1 mg / kg or more, 0.25 mg / kg or more, 0.5 mg / kg or more, 1 mg / kg or more, 2.5 mg / kg or more, 0.5 mg / kg or more, 1.0 mg / kg or more, 2.0 mg / kg or more, 3.0 mg / kg or more, 4.0 mg / kg or more, 5 mg / kg or more, 10 mg / kg or more, 20 mg / kg or more, 30 mg / kg or more, 40 mg / kg or more, 50 mg / kg or more, 75 mg / kg or more, 100 mg / kg or more, 150 mg / kg or more, 200 mg / kg or more, 300 mg / kg or more, 400 mg / kg or more, or 500 mg / kg or more, for example, 0.001 mg / kg to 500 mg / kg. Any amount within the mg / kg range (e.g., 0.001 mg / kg, 0.01 mg / kg, 0.1 mg / kg, 1 mg / kg, 5 mg / kg, 10 mg / kg, 50 mg / kg, 100 mg / kg, or 200 mg / kg) can be appropriately selected. For example, the dose per administration may be 0.1 mg to 200 mg.

[0131] The nucleic acid agent or double-stranded nucleic acid complex of the present invention may be administered twice a week for four doses at a dose of 0.01 to 10 mg / kg (e.g., about 6.25 mg / kg). Alternatively, the nucleic acid agent or double-stranded nucleic acid complex may be administered once or twice a week for two to four doses at a dose of 0.05 to 30 mg / kg (e.g., about 25 mg / kg), for example, twice a week for two doses. The use of such a dosing regimen (divided administration) can reduce toxicity (e.g., avoid platelet reduction) and alleviate the burden on the subject compared to a single administration of a higher dose.

[0132] The pharmaceutical composition exerts an additive inhibitory effect within cells even when administered repeatedly. Furthermore, when administering repeatedly, the efficacy can be improved by leaving a certain interval between administrations (e.g., half a day or more).

[0133] The present invention will be described in more detail below using examples, although the technical scope of the present invention is not limited to these examples.

[0134] Example 1: Formation of self-G-quadruplex (self-Gq) structure (Objective) A guanine repeat sequence consisting of the base sequence GGG can form a stable nucleic acid higher-order structure called a G-quadruplex (Gq) structure. When four guanine repeat sequences form a G-quadruplex on mRNA, protein translation can be inhibited.

[0135] A nucleic acid strand containing an antisense sequence complementary to a target RNA and a G-quadruplex sequence is called a "G-tethered ASO" or "g-AS." The antisense sequence of a g-AS hybridizes to the target RNA, and the G-quadruplex sequence can form a G-quadruplex with the G-quadruplex sequence in the target RNA. The region between the hybridized antisense sequence and the G-quadruplex-forming G-quadruplex sequence in the target RNA forms a loop, which inhibits functions such as splicing and reverse transcription through steric hindrance (Figures 1 and 2).

[0136] In this example, we examine the possibility that g-ASs can form G-quadruplex structures with guanine repeat sequences in target RNAs, as well as between multiple g-ASs.

[0137] (Methods and Results) (1) Preparation of 5'g-AS(a)-original 5'g-AS(a)-original, shown in Table 1 below, was prepared as a g-AS targeting the region located near the boundary with intron 23 in exon 23 of the dystrophin gene of mdx mice (Duchenne muscular dystrophy model mice).

[0138]

[0139] 5'g-AS(a)-original contains, from the 5' end, a triplet of GGG linked via a T base (hereinafter, the GGG sequence contained in g-AS is referred to as the "consecutive guanine sequence"), a spacer sequence, and a target-binding sequence. The target-binding sequence is complementary to a target sequence located near the boundary between exon 23 and intron 23 in the dystrophin gene of mdx mice (a model mouse of Duchenne muscular dystrophy) ("target sequence (a)" shown in a black box in Figure 3). The triplet of guanines contained in the 5' end of 5'g-AS(a)-original targets a guanine repeat sequence consisting of the GGG sequence located at positions 64 to 66 of intron 23 of the dystrophin gene, starting from the base adjacent to exon 23 (the "GGG sequence" shown in a black box in Figure 3).

[0140] 5'g-AS(a)-original was synthesized by Gene Design Co., Ltd. and Hokkaido System Science Co., Ltd.

[0141] (2) Preparation of target mdx RNA The RNA targeted by 5'g-AS(a)-original was prepared as follows. First, the nucleotide sequence (SEQ ID NO: 1, Figure 3) containing intron 22, exon 23, and intron 23 in the dystrophin gene of mdx mice (a model mouse of Duchenne muscular dystrophy) was inserted into the GFP sequence of the pEGFP-N1 vector to prepare the pEGFP-N1 mdx Exon 23 insert vector. This pEGFP-N1 mdx Exon 23 insert vector is designed so that GFP is expressed only when exon 23 is skipped in the transcript transcribed from the vector.

[0142] Next, cloning into the pUC19 vector was performed as follows. Using the pEGFP-N1 mdx Exon23 insert vector as a template, PCR amplification was performed using the primer pair shown in SEQ ID NOs: 9 and 10 and PrimeSTAR® Max DNA Polymerase (Takara Bio). The resulting PCR product was used as insert DNA. The insert DNA was then cleaved with the restriction enzyme BamH1 (Takara Bio), and the resulting fragment was introduced into the BamH1 site of the pUC19 vector (Takara Bio), creating the pUC19 mdx Exon23 insert vector.

[0143] Using the pUC19 mdx Exon23 insert vector as a template, PCR amplification was performed using the primer pair shown in SEQ ID NOs: 11 and 12 and PrimeSTAR Max DNA Polymerase (Takara Bio). The resulting PCR product was used as a template for a transcription reaction using the ScriptMAX® Thermo T7 Transcription Kit (TOYOBO). DNA was then digested with DNase I (Nippon Gene) to obtain the target mdx RNA used as the target RNA in (3) below.

[0144] (3) Evaluation of G-quadruplex formation (i) G-quadruplex formation between 5'g-AS(a)-original and target RNA. To evaluate the efficiency of G-quadruplex formation between 5'g-AS(a)-original and target RNA, a thioflavin T (ThT) assay was performed. Specifically, 5'g-AS(a)-original (6.25 μM) prepared in (1) above, target mdx RNA (5.0 μM) prepared in (2) above, KCl (10 mM), Tris-HCl (pH 7.6, 50 mM), and PEG200 (20 wt%) were mixed to the indicated concentrations. The mixture was then incubated at 95°C for 2 minutes, followed by cooling to 4°C at 1°C per minute, allowing for annealing. Thioflavin T (5 μM) was then added to the indicated concentration, mixed, and incubated at 37°C for 60 minutes. After incubation, the mixture was irradiated with 440 nm excitation light using an Infinite M1000 PRO (TECAN) and the fluorescence spectrum was measured in the wavelength range of 450 nm to 600 nm.

[0145] (ii) G-quadruplex formation between 5'g-AS(a) and original. To evaluate the efficiency of G-quadruplex formation between multiple g-ASs, we performed a ThT assay using the same method as in (i) above, but without the addition of target mdx RNA.

[0146] The results of (i) and (ii) above are shown in Figure 5A. 5'g-AS(a)-original exhibited a fluorescence peak at 480 nm to 500 nm, indicating a G-quadruplex structure, in the presence of target RNA (Figure 5A, "RNA + g-AS"). On the other hand, a similar fluorescence peak was detected in the absence of target RNA, demonstrating that 5'g-AS(a)-original forms a G-quadruplex structure with each other (Figure 5A, "g-AS").

[0147] These results revealed that g-AS not only forms G-quadruplexes with the guanine repeats in target RNA, but also with other g-AS (Figure 5B). In the following examples, the G-quadruplex formed between g-AS and other g-AS is referred to as the "self-Gq" or "self-Gq" to distinguish it from the G-quadruplex formed between g-AS and target RNA (hereafter referred to as the "targeted Gq" or "targeted Gq"). It is possible that the self-Gq interferes with the formation of the targeted Gq. Conversely, suppressing the self-Gq could improve the efficiency of targeted Gq formation and potentially improve the efficacy of g-AS.

[0148] Example 2: Development of a single-base-inserted g-AS and evaluation of the rate of self-Gq formation (Objective) To develop a new g-AS that suppresses the formation of self-G-quadruplexes. Specifically, to verify whether the formation of self-G-quadruplexes is reduced by inserting a single base other than G into one of the three guanine repeats of 5'g-AS(a)-original.

[0149] (Methods and Results) (1) Preparation of Single-Base-Inserted g-AS To suppress the formation of self-G-quadruplex structures, we developed a g-AS in which a single base other than G was inserted into one of the three consecutive guanine sequences contained in the g-AS (hereinafter referred to as "single-base-inserted g-AS"). In the following examples, a sequence in which a base X other than G is inserted into a consecutive guanine sequence consisting of the base sequence GGG (base sequence GXGG or base sequence GGXG) is referred to as a "guanine-rich sequence" to distinguish it from a consecutive guanine sequence without an inserted base.

[0150] The various g-AS prepared in this example are shown in Table 2 below and FIG.

[0151]

[0152] The 5'g-AS(a)-original shown in Table 2 is similar to that described in Example 1 and contains, from the 5'-terminus, three consecutive guanine sequences linked via a T base, a spacer sequence, and a target-binding sequence. 5'g-AS(a)1-1 to 5'g-AS(a)3-2 contain, from the 5'-terminus, two consecutive guanine sequences linked via a T base, one guanine-rich sequence, a spacer sequence, and a target-binding sequence, but differ in the position of the guanine-rich sequence and the position of the T base inserted in the guanine-rich sequence (Figure 4, arrow position). The target-binding sequence contained in each g-AS consists of a base sequence complementary to a target sequence located near the boundary between exon 23 and intron 23 in the dystrophin gene of mdx mice (a model mouse of Duchenne muscular dystrophy) (Figure 3, "target sequence (a)" indicated by a solid black box).

[0153] The above g-AS were synthesized by Gene Design Co., Ltd. and Hokkaido System Science Co., Ltd.

[0154] (2) Evaluation of self-G-quadruplex formation To evaluate the self-G-quadruplex formation of the g-AS prepared in (1) above, a ThT assay was performed on each g-AS in the absence of target mdx RNA, using the same method as in (ii) of “(3) Evaluation of G-quadruplex formation” in Example 1.

[0155] The results of the ThT assay are shown in Figure 6. The single-base-insertion g-ASs, 5'g-AS(a)1-1, 5'g-AS(a)1-2, 5'g-AS(a)2-1, 5'g-AS(a)2-2, and 5'g-AS(a)3-2, showed reduced self-G-quadruplex formation compared to 5'g-AS(a)-original, which does not contain a single-base insertion in the consecutive guanine sequence. In particular, 5'g-AS(a)2-1 showed a greater than 70% reduction in self-G-quadruplex formation as measured by the ThT fluorescence signal ratio.

[0156] Example 3: Evaluation of the targeted Gq formation rate of single-base-inserted g-AS (Objective) The single-base-inserted g-AS prepared in Example 2 was evaluated for its efficiency in forming a G-quadruplex structure with the target RNA.

[0157] (Method and Results) To evaluate the efficiency of G-quadruplex (targeted Gq) formation between the single-base-inserted g-AS prepared in (1) of Example 2 and the target RNA, a ThT assay was performed on the single-base-inserted g-AS in the presence of target mdx RNA using a method similar to that described in (i) of "(3) Evaluation of G-quadruplex formation" in Example 1. In this example, 5'g-AS(a)2-1 prepared in (1) of Example 2 was used as an example of a single-base-inserted g-AS, and 5'g-AS(a)-original, which does not contain a single-base insertion, was used for comparison.

[0158] The results of the ThT assay are shown in Figure 7. The single-base-inserted g-AS, 5'g-AS(a)2-1, showed a decreased rate of spontaneous Gq formation (Figure 7, "g-AS") compared with the control, 5'g-AS(a)-original, while the targeted Gq formation rate (Figure 7, "RNA+g-AS") was equal to or greater than that. Figure 8 shows the relative values ​​of the peak fluorescence intensity (corresponding to spontaneous Gq formation rate) in the presence of target mdx RNA, relative to the peak fluorescence intensity (corresponding to targeted Gq formation rate) in the absence of target mdx RNA. While 5'g-AS(a)-original showed a 1.31-fold increase in Gq formation rate in the presence of target mdx RNA, the single-base-inserted g-AS, 5'g-AS(a)2-1, showed a 2.31-fold increase in Gq formation rate in the presence of target mdx RNA, a rate of change of more than 1.7-fold. These results indicated that the single-base-inserted g-AS significantly improved its ability to form Gq with the target RNA by suppressing its own Gq formation rate.

[0159] Based on the above results, it is thought that the insertion of a single base into a g-AS sequence of consecutive guanines does not significantly affect the stability of the G-quadruplex formed with the base sequence GGG in the target RNA (Fig. 9A). However, it may have a greater effect on the stability of the G-quadruplex formed by multiple g-ASs, for example, by increasing the probability that the nucleic acid strands that make up the G-quadruplex contain multiple base insertions (Fig. 9B).

[0160] Example 4: Induction of exon skipping by single-base-insertion g-AS (Objective) Using the single-base-insertion g-AS prepared in Example 2, exon skipping is induced (1) in cultured cells and (2) in vivo in mice.

[0161] (Methods and Results) 5'g-AS(2'OMe)2-1 shown in Table 3 below was prepared and used to induce exon skipping.

[0162]

[0163] 5'g-AS(2'OMe)2-1 shown in Table 3 above comprises, from the 5'-terminus, two consecutive guanine sequences and one guanine-rich sequence linked via a T base, a spacer sequence, and a target-binding sequence, in which the nucleosides of the target-binding sequence are composed of 2'-OMe RNA, and the remaining nucleosides are composed of DNA. The target-binding sequence comprises a base sequence complementary to a target sequence including the boundary between exon 23 and intron 23 in the dystrophin gene of mdx mice (a model mouse of Duchenne muscular dystrophy).

[0164] (1) Cultured Cells. Exon skipping was induced in HEK293 cells. 1 ng of the pEGFP-N1 mdx Exon23 insert vector (designed to express GFP only when exon 23 is skipped in the transcript transcribed from the vector) prepared in Example 1 and 1,000 ng of 5'g-AS(2'OMe)2-1 or control 5'g-AS(2'OMe) original were diluted with 50 μL of Opti-MEM® (Thermo Fisher Scientific) to prepare a diluted DNA solution. Note that 5'g-AS(2'OMe) original is a g-AS in which all nucleosides in the target binding sequence of 5'g-AS(a)-original prepared in Example 1 were replaced with 2'-OMe RNA. 2.5 μL of Lipofectamine® 2000 (Thermo Fisher Scientific) was diluted with 50 μL of Opti-MEM®, added to the DNA solution, and incubated at room temperature for 5 minutes. The entire solution was added to HEK293 cells and cultured in a CO2 incubator for 24 hours. RNA was extracted from HEK293 cells using ISOGENII. 500 ng of the resulting RNA was reverse-transcribed using the PrimeScript One Step RT-PCR Kit (Takara Bio). PCR amplification was performed using the resulting cDNA as a template and the primer pair shown in SEQ ID NOs: 14 and 15. The amplified product was electrophoresed on an agarose gel (2% agarose, 10% Gel Red) at 100 V for 30 minutes and imaged using a ChemiDoc Touch Imaging System (BIO-RAD). The number of nucleotide moles of the band in which exon 23 was skipped ("A") and the number of nucleotide moles of the band in which exon 23 was not skipped ("B") were measured. Based on the values ​​of "A" and "B," the skipping efficiency was calculated according to the following formula: skipping efficiency (%) = A / (A + B) × 100.

[0165] The electrophoresis results are shown in Figure 10-1B. When exon 23 was skipped, a 141-bp nucleic acid fragment was amplified (Figure 10-1A). When 5'g-AS(2'OMe)2-1 was introduced into cultured cells, a 141-bp nucleic acid fragment was detected, demonstrating that exon skipping was induced more efficiently than with the control 5'g-AS(2'OMe) original (Figures 10-1B and 10-1C, p<0.01).

[0166] When conventional g-AS without a single-base insertion is used at high concentrations, the physical distance between g-AS molecules is reduced, which may increase the formation of self-G-quadruplexes between g-AS molecules and reduce the ability to form RNA-DNA heteroquadruplexes between the target RNA and g-AS. However, the single-base insertion g-AS of the present invention suppresses self-G-quadruplex formation even when used at high concentrations, thereby maintaining high efficiency of RNA-DNA heteroquadruplex formation between the target RNA and g-AS. Therefore, the single-base insertion g-AS of the present invention enables dose-dependent adjustment of therapeutic effects and is considered to have high clinical applicability.

[0167] (2) In vivo validation To verify the in vivo efficacy of g-AS in inducing RNA-DNA heteroG-quadruplex structures, we performed an exon skipping assay using mdx mice, an established animal model of DMD.

[0168] Mdx mice were housed in a controlled environment with a 12-hour light / dark cycle. All mice were maintained in accordance with the ethical guidelines of Tokyo Medical and Dental University. 10 nmol of 5'g-AS(2'OMe) original or 5'g-AS(2'OMe)2-1 was dissolved in 36 μL. Four- to six-week-old mdx mice were intramuscularly injected with each g-AS into the tibialis anterior muscle. One week after administration, the mdx mice were dissected. Muscle tissue samples were collected from the treated mdx mice, and RNA was extracted using ISOGEN II® (NIPPON GENE). Reverse transcription PCR (RT-PCR) was performed using 500 ng of extracted RNA as a template using the PrimeScript One Step RT-PCR Kit® (Takara Bio). PCR amplification and analysis were performed to evaluate the exon skipping efficiency in dystrophin transcripts. PCR was performed using the primer pair shown in SEQ ID NOs: 14 and 15, with the complementary DNA (cDNA) obtained by RT-PCR as a template. The amplified PCR products were electrophoresed on an agarose gel (2% agarose, 10% Gel Red) at 100 V for 30 minutes and photographed using a ChemiDoc Touch imaging system (BIO-RAD). Quantitative evaluation of PCR products to measure exon skipping efficiency was performed using an Agilent 2100 bioanalyzer® (Agilent Technologies).

[0169] The results are shown in Figure 10-2. It was found that exon 23 skipping was promoted when both 5'g-AS(2'OMe) original and 5'g-AS(2'OMe)2-1 were administered intramuscularly to mdx mice. 5'g-AS(2'OMe)2-1 showed a higher exon skipping efficiency than 5'g-AS(2'OMe) original (p<0.05). These results demonstrate that even in pathological models, the single-base-inserted g-AS exhibits a higher exon skipping efficiency than the conventional g-AS without the single-base insertion.

[0170] Example 5: Inhibition of reverse transcription reaction by single-base-inserted g-AS (Objective) The single-base-inserted g-AS prepared in Example 2 is used to inhibit reverse transcription reaction.

[0171] (Method and Results) The inhibitory effect on reverse transcription reaction was verified using the following method. Target mdx RNA (0.5 μM) prepared in "(2) Preparation of target mdx RNA" in Example 1, 5'g-AS(a)2-1 (1 μM) prepared in Example 2, or the control 5'g-AS(a)-original (1 μM) prepared in Example 1, the fluorescently labeled primer (5'-FAM-CGCCAGGGTTTTCCCAGTCACGAC-3') (SEQ ID NO: 16) (30 nM), KCl (10 mM), Tris-HCl (pH 7.6, 50 mM), and PEG200 (20 wt%) were mixed to the concentrations indicated. The mixture was then incubated at 95°C for 2 minutes, followed by cooling to 4°C at a rate of 1°C per minute, allowing for annealing. Subsequently, reverse transcription reaction was carried out using ReverTra Ace (registered trademark) qPCR RT Master Mix (TOYOBO) in a solution containing dNTP (0.87 mM) and MgCl2 (5 mM) at 42°C for 30 minutes.

[0172] When the single-base-inserted g-AS forms a G-quadruplex with the guanine repeat sequence in the target mdx RNA (the GGG sequence located at positions 64-66, starting from the base adjacent to exon 23 in intron 23 of the dystrophin gene), and the reverse transcription reaction is terminated by steric hindrance at that position, a cDNA shorter than the full-length is detected by fragment analysis (Figures 11-1A and 11-1B).

[0173] The results of fragment analysis are shown in Figure 11-1C. In the presence of 5'g-AS(a)2-1, only one large peak representing a cDNA shorter than the full-length was detected. This peak coincided with the GGG sequence (positions 64-66, starting from the base adjacent to exon 23 in intron 23 of the dystrophin gene), where G-quadruplex formation is predicted. In contrast, in the presence of the control 5'g-AS(a)-original, two large peaks representing a shorter cDNA were detected. These peaks corresponded to the same GGG sequence as above, as well as to the GAGG sequence located 56 bases upstream of the GGG sequence (positions 8-11, starting from the base adjacent to exon 23 in intron 23 of the dystrophin gene). Furthermore, when reverse transcription was performed in the absence of g-AS, no significant peaks were detected other than the peak corresponding to the full-length cDNA. These results indicate that the single-base-inserted g-AS efficiently inhibits reverse transcription of the target RNA at the GGG sequence, while suppressing G-quadruplex formation at the GAGG sequence, which is similar to the GGG sequence. Therefore, it was revealed that the single-base-inserted g-AS has improved specificity for the GGG sequence and reduced off-target effects (Figure 11-2).

[0174] Example 6: Single-base-inserted g-AS with consecutive guanine sequences and a guanine-rich sequence on the 3' side (Objective) To create a single-base-inserted g-AS in which consecutive guanine sequences and a guanine-rich sequence are located on the 3' side of the target-binding sequence, and to examine the efficiency of forming a self-G-quadruplex structure.

[0175] (Methods and Results) (1) Preparation of Single-Base Insertion Type g-AS Various g-AS shown in Table 4 and FIG. 12 were prepared by the same method as in Example 2.

[0176]

[0177] The 3'g-AS(a)-original shown in Table 4 contains, from the 5' end, a target-binding sequence, a spacer sequence, and three consecutive guanine sequences linked via a T base. 3'g-AS(a)1-1 to 3'g-AS(a)3-2 contain, from the 5' end, a target-binding sequence, a spacer sequence, two consecutive guanine sequences linked via a T base, and one guanine-rich sequence. The positions of the guanine-rich sequences and the positions of the T bases inserted in the guanine-rich sequences differ (Figure 12, arrows). The target-binding sequence contained in each g-AS consists of a base sequence complementary to a target sequence located near the boundary between exon 23 and intron 23 in the dystrophin gene of mdx mice (a model mouse of Duchenne muscular dystrophy) (Figure 3, "target sequence (a)" indicated by a solid black box).

[0178] The above g-AS were synthesized by Gene Design Co., Ltd. and Hokkaido System Science Co., Ltd.

[0179] (2) Evaluation of self-G-quadruplex formation To evaluate the self-G-quadruplex formation of the g-AS prepared in (1) above, a ThT assay was performed on each g-AS in the absence of target mdx RNA, using the same method as in (ii) of “(3) Evaluation of G-quadruplex formation” in Example 1.

[0180] The results of the ThT assay are shown in Figure 13. The single-base-insertion g-AS, 3'g-AS(a)1-2, 3'g-AS(a)2-1, 3'g-AS(a)2-2, 3'g-AS(a)3-1, and 3'g-AS(a)3-2, showed reduced rates of self-G-quadruplex formation compared to 3'g-AS(a)-original, which does not contain a single-base insertion in the consecutive guanine sequence. In particular, 3'g-AS(a)2-1 and 3'g-AS(a)2-2 showed significantly reduced rates of self-G-quadruplex formation.

[0181] Example 7: Single-base-inserted g-AS containing a different target-binding sequence (Objective) A single-base-inserted g-AS containing a target-binding sequence different from that of the above examples was prepared, and the formation of a self-G-quadruplex structure was investigated.

[0182] (Methods and Results) (1) Preparation of Single-Base Insertion Type g-AS Using the same method as in Example 2, various g-AS shown in Tables 5 and 6 below and in Figures 14 and 16 were prepared.

[0183]

[0184] The 5'g-AS(b)-original shown in Table 5 contains, from the 5' end, three consecutive guanine sequences linked by a T base, a spacer sequence, and a target-binding sequence. The 5'g-AS(b)1-1 to 5'g-AS(b)3-2 contain, from the 5' end, two consecutive guanine sequences linked by a T base, one guanine-rich sequence, a spacer sequence, and a target-binding sequence. The positions of the guanine-rich sequences and the insertion positions of T bases in the guanine-rich sequences differ (Figure 14, arrows). The target-binding sequence contained in each g-AS consists of a base sequence complementary to a target sequence (Figure 3, "target sequence (b)") that includes the boundary between exon 23 and intron 23 in the dystrophin gene of mdx mice (a model mouse of Duchenne muscular dystrophy).

[0185]

[0186] The 3'g-AS(b)-original shown in Table 6 contains, from the 5' end, a target-binding sequence, a spacer sequence, and three consecutive guanine sequences linked by a T base. 3'g-AS(b)1-1 to 3'g-AS(b)3-2 contain, from the 5' end, a target-binding sequence, a spacer sequence, two consecutive guanine sequences linked by a T base, and one guanine-rich sequence. The positions of the guanine-rich sequences and the insertion positions of the T bases in the guanine-rich sequences differ (Figure 16, arrows). The target-binding sequence contained in each g-AS is complementary to a target sequence (Figure 3, "target sequence (a)") that includes the boundary between exon 23 and intron 23 in the dystrophin gene of mdx mice (a model mouse of Duchenne muscular dystrophy).

[0187] The above g-AS were synthesized by Gene Design Co., Ltd. and Hokkaido System Science Co., Ltd.

[0188] (2) Evaluation of self-G-quadruplex formation To evaluate the self-G-quadruplex formation of the g-AS prepared in (1) above, a ThT assay was performed on each g-AS in the absence of target mdx RNA, using the same method as in (ii) of “(3) Evaluation of G-quadruplex formation” in Example 1.

[0189] The results of the ThT assay are shown in Figures 15 and 17. The single-base-insertion g-ASs 5'g-AS(b)1-1, 5'g-AS(b)1-2, 5'g-AS(b)2-1, 5'g-AS(b)2-2, 5'g-AS(b)3-1, and 5'g-AS(b)3-2 showed reduced rates of self-G-quadruplex formation compared to 5'g-AS(b)-original, which does not contain a single-base insertion in the consecutive guanine sequence. In particular, 5'g-AS(b)2-1, 5'g-AS(b)2-2, and 5'g-AS(b)3-2 showed significantly reduced rates of self-G-quadruplex formation. Furthermore, the single-base-inserted g-AS, 3'g-AS(b)1-2, 3'g-AS(b)2-1, 3'g-AS(b)2-2, 3'g-AS(b)3-1, and 3'g-AS(b)3-2, showed a significantly reduced rate of self-G-quadruplex formation compared to 3'g-AS(b)-original, whose consecutive guanine sequence does not contain a single-base insertion. All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.

Claims

1. A nucleic acid agent capable of binding to a target nucleic acid molecule containing a guanine repeat sequence consisting of the base sequence GGG, the nucleic acid agent comprising: a target binding sequence comprising a base sequence complementary to at least a portion of the target nucleic acid molecule; two consecutive guanine sequences, each consisting of the base sequence GGG; and a guanine-rich sequence consisting of the base sequence GXGG or GGXG, wherein X represents a base other than G or C or an abasic site, the two consecutive guanine sequences, the guanine-rich sequence, and the guanine repeat sequence are capable of forming a guanine-quadruplex structure that is more stable than a guanine-quadruplex structure that a plurality of the nucleic acid agents can form together.

2. The nucleic acid agent described in claim 1, wherein the two consecutive guanine sequences and the guanine-rich sequence are located on the 5'-end or 3'-end side of the target binding sequence.

3. The nucleic acid agent described in claim 2, wherein the guanine-rich sequence is located on the 5'-terminus or 3'-terminus side of the two consecutive guanine sequences, or between them.

4. The nucleic acid agent of claim 2, wherein the guanine-rich sequence is positioned between the two consecutive guanine sequences.

5. (a) in the nucleic acid agent, the two consecutive guanine sequences and the guanine-rich sequence are located on the 5'-end side of the target binding sequence, and (ai) the guanine-rich sequence is located on the 5'-end side of the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG; (a-ii) the guanine-rich sequence is located between the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG; or (a-iii) the guanine-rich sequence is located on the 3'-end side of the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GGXG; or (b) in the nucleic acid agent, the two consecutive guanine sequences and the guanine-rich sequence are located on the 3'-end side of the target binding sequence, and (bi) the guanine-rich sequence is located on the 5'-end side of the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GGXG; The nucleic acid agent according to claim 1, wherein (b-ii) the guanine-rich sequence is located between the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG, or (b-iii) the guanine-rich sequence is located on the 3'-terminal side of the two consecutive guanine sequences, and the guanine-rich sequence consists of the base sequence GXGG or GGXG, wherein X in the base sequence represents a base other than a G base or a C base, or an abasic site.

6. The nucleic acid agent described in claim 3, which comprises a linker sequence composed of one or more bases other than G or C between any two adjacent sequences of the two consecutive guanine sequences and the guanine-rich sequence.

7. The nucleic acid agent according to claim 6, wherein the linker sequence is 1 to 30 bases in length.

8. The nucleic acid agent of claim 2, comprising a spacer sequence or spacer molecule between the two consecutive guanine sequences and the guanine-rich sequence and the target binding sequence.

9. The nucleic acid agent according to claim 8, wherein the spacer sequence is 1 to 10 bases in length.

10. The nucleic acid agent of claim 2, which does not include a spacer sequence between the two consecutive guanine sequences and the guanine-rich sequence and the target binding sequence.

11. The nucleic acid agent described in claim 1, which does not contain the base sequence GGG and / or does not contain the base sequence CCC other than the two consecutive guanine sequences.

12. The nucleic acid agent of claim 1, wherein X is T, A, or U.

13. The nucleic acid agent according to claim 1, wherein the nucleoside containing a guanine base in the guanine-rich sequence and the nucleoside containing the base represented by X are a ribonucleoside and a deoxyribonucleoside, respectively, or a deoxyribonucleoside and a ribonucleoside, respectively.

14. The nucleic acid agent of claim 1, wherein the target binding sequence is 12 to 30 bases in length.

15. The nucleic acid agent of claim 1, comprising natural nucleosides and / or non-natural nucleosides.

16. The nucleic acid agent of claim 15, wherein the unnatural nucleoside is selected from the group consisting of a 2'-modified nucleoside, a 5'-modified nucleoside, and a bridged nucleoside.

17. The nucleic acid agent of claim 1, comprising or consisting of a morpholino nucleic acid.

18. The nucleic acid agent of claim 1, wherein all or a portion of the internucleoside linkages of the nucleic acid agent are modified internucleoside linkages.

19. The nucleic acid agent of claim 18, wherein the modified internucleoside linkage is a phosphorothioate linkage.

20. The nucleic acid agent of claim 1, comprising a modified nucleobase.

21. The nucleic acid agent of claim 1, wherein the target nucleic acid molecule comprises a loop-forming sequence between the target sequence to which the target binding sequence binds and the guanine repeat sequence.

22. The nucleic acid agent according to claim 21, wherein the loop-forming sequence is 1 to 500 bases in length.

23. The nucleic acid agent of claim 1 for inducing steric blocking of the target nucleic acid molecule.

24. The nucleic acid agent described in claim 1, wherein the target nucleic acid molecule is a target gene or its transcription product.

25. The nucleic acid agent described in claim 24 for inducing exon skipping or exon inclusion in the transcript.

26. The nucleic acid agent of claim 1, wherein the target nucleic acid molecule is RNA or DNA.

27. The nucleic acid agent of claim 26, wherein the RNA is mRNA or a precursor thereof, non-coding RNA, or viral RNA.

28. The nucleic acid agent of claim 27 for inhibiting translation of the mRNA.

29. The nucleic acid agent of claim 27 for suppressing or inhibiting reverse transcription of the viral RNA.

30. A double-stranded nucleic acid complex comprising a first nucleic acid strand comprising the nucleic acid agent described in claim 1 and a second nucleic acid strand comprising a base sequence complementary to the first nucleic acid strand.

31. The double-stranded nucleic acid complex of claim 30, wherein the second nucleic acid strand comprises ribonucleosides, deoxyribonucleosides, and / or modified nucleosides.

32. The double-stranded nucleic acid complex described in claim 30, wherein the second nucleic acid strand comprises: bases non-complementary to the first nucleic acid strand; an insertion sequence and / or a deletion; and / or at least one overhang region located on the 5'-end and / or 3'-end side of a region consisting of a base sequence complementary to the first nucleic acid strand.

33. The double-stranded nucleic acid complex according to claim 32, wherein the overhang region is 1 to 30 bases in length.

34. The double-stranded nucleic acid complex of claim 30, wherein the second nucleic acid strand is linked to a functional moiety.

35. The double-stranded nucleic acid complex of claim 34, wherein the functional moiety is a lipid.

36. The double-stranded nucleic acid complex of claim 35, wherein the lipid is selected from the group consisting of cholesterol or an analogue thereof, tocopherol or an analogue thereof, folic acid, phosphatidylethanolamine, and a substituted or unsubstituted hydrocarbon group having 16 to 30 carbon atoms.

37. The double-stranded nucleic acid complex of claim 30, wherein the first nucleic acid strand and the second nucleic acid strand are linked via a linker.

38. The double-stranded nucleic acid complex of claim 37, wherein the linker is a cleavable or uncleavable linker.

39. A pharmaceutical composition comprising a nucleic acid agent according to any one of claims 1 to 29, or a double-stranded nucleic acid complex according to any one of claims 30 to 38.

40. The pharmaceutical composition according to claim 39 for treating or preventing a neuromuscular disease, an infectious disease, an inflammatory disease, a cancer, an immune disease, an ischemic disease, or a metabolic disease.

41. The pharmaceutical composition of claim 40, wherein the neuromuscular disease is a neurological disease, a muscular disease, a neuromuscular junction disease, a neurodegenerative disease, or a muscular dystrophy.

42. The pharmaceutical composition of claim 40, wherein the infectious disease is a viral infection.

43. The pharmaceutical composition of claim 39, which is administered intravenously, subcutaneously, intramuscularly, intrathecally, orally, intraperitoneally, intranasally, or by inhalation.

44. The pharmaceutical composition of claim 39, wherein the nucleic acid agent or the double-stranded nucleic acid complex is administered in an amount of 0.1 mg to 200 mg.

Citation Information

Patent Citations

  • Chimeric double-stranded nucleic acids

    JP2015502134A

  • New staple nucleic acid

    WO2023224102A1